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1. Introduction and objectives 
 
The size of an animal depends on the number and volume of the cells it contains, with some 
contribution by extracellular matrix and fluids. In mammals, growth (increase in size) begins 
at pre-implantational embryonic stages and lasts until a steady state is reached postnatally. 
Appropriate growth is controlled by hormones and growth factors regulating cellular signaling 
pathways.  
 
In mice, the insulin-like growth factor system has been unequivocally identified as the major 
determinant of both embryonic and postnatal (here modulated by the growth hormone - GH) 
growth (Lupu et al., 2001). The IGF system consists of two ligands (IGF-I and IGF-II), two 
receptors (IGF-IR and IGF-IIR) and six high affinity IGF binding proteins (IGFBP-1 to -6). 
The single chain peptide growth factors IGF-I and -II are produced by several tissues and 
function in an autocrine/paracrine fashion and, since they circulate in the plasma bound to the 
IGFBPs, as classical hormones. Despite their structural homology, each growth factor has 
specific expression patterns and actions in regulating proliferation, differentiation, survival 
and specific functions of many cell types and tissues under different physiological and 
pathological conditions (Stewart and Rotwein, 1996). 
The actions of both growth factors are mediated via the IGF-IR. In contrast, the structurally 
distinct IGF-IIR is not considered to play a role in IGF signal transduction, but is responsible 
for the turnover of IGF-II by receptor-mediated endocytosis, thereby reducing the levels of 
circulating IGF-II (Le Roith et al., 1995; Kornfeld et al., 1992). 
 
To gain insight into the functions of the IGF system during embryogenesis and postnatal 
development several transgenic and knockout mouse models for the members of the IGF 
family have been established over the last decades. 
Homozygous IGF-I deficient mice have ~60% of normal weight (N) at birth and become 
~30% of N at an age of 2 months, indicating that IGF-I not only is necessary for normal 
embryonic growth, but also has a continuous function throughout postnatal development (liu 
et al., 1993). IGF-II nullizygotes are also born with ~60% but do not display a further size 
reduction, maintaining ~60% N at steady state, suggesting that this growth factor is only 
essential for normal embryonic growth (DeChiara et al., 1990). 
 
Whereas adult humans display unaltered high levels of IGF-II, in mice and rats expression of 
IGF-II is shut down in almost every tissue after birth and very low levels of this growth factor 
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are detectable in postnatal life (Rotwein et al., 1991). Overexpression of IGF-II in transgenic 
mice resulted in disproportionate growth of specific organs but not in a significant increase in 
body size. In some cases an increased tumor formation could be detected, which is in line 
with the frequent observation of overexpression of IGF-II in a variety of human malignancies 
(Wolf et al., 1998). 
 
The objective of the investigations reported here was to study the role of postnatally elevated 
IGF-II in the absence of IGF-I. Therefore we employed two available mouse models (IGF-I 
knockout and PEPCK-IGF-II transgenic mice) to generate mice harboring a homozygous 
deletion of the Igf1 gene and overexpressing IGF-II at the same time. To test whether an 
overexpression of IGF-II is able to rescue phenotypic consequences of homozygous IGF-I 
deficiency in mice, body and organ growth, bone parameters (size, mineral density), and 
regulatory mechanisms of serum IGFBP and GH homeostasis were investigated. 
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2  Review of the literature 
 
2.1   The insulin-like growth factor (IGF) system 
 
2.1.1 Overview 
 
The early history of insulin-like growth factors started in 1957 when William D. Salmon, Jr. 
and William H. Daughaday tried to set up an in vitro assay for growth hormone (GH). This 
assay should demonstrate a direct effect of GH on radioactively labeled sulfate (35S-sulfate) 
uptake in cartilage of hypophysectomized rats. However, the addition of bovine GH turned 
out to be virtually inactive. Next, they compared the effects of incubation of these cartilage 
segments with diluted serum of normal or hypophysectomized rats. 35S-sulfate uptake in the 
presence of normal serum was 200% greater than that in hypophysectomized rat serum, 
leading them to suggest that the effect of GH was attributable to an inducible “sulfation 
factor” (Salmon et al., 1957; Daughaday, 1992;  Daughaday, 2000). Subsequently, the 
sulfation factor was renamed somatomedin C (Daughaday et al., 1972). 
Independently, in the 1960s a serum activity was identified that lowered glucose levels even 
in the presence of anti-insulin antibodies (Froesch et al., 1963). These serum components 
were designated nonsuppressible insulin-like activity (NSILA). Additionally, a protein 
synthesized by the liver, which could enhance cell replication was described (Dulak and 
Temin, 1973; Nissley et al., 1976). It was termed multiplication stimulating activity (MSA). 
Initial purification of these three substances, revealed that they have overlapping activities. To 
indicate the relationship of these substances to insulin and to emphasize their growth 
promoting activities, the term insulin-like growth factor was proposed by Rinderknecht and 
Humbel (1976). With purification and sequencing of human IGF-I (Rinderknecht and 
Humbel, 1978a) and IGF-II (Rinderknecht and Humbel, 1978b), it became evident that 
somatomedin C was ultimately IGF-I, MSA corresponded to IGF-II and that NSILA included 
both growth factors. IGF-I and IGF-II are ~70% identical to one another, and their A and B 
domains are 50% identical to the A and B chains of human insulin, indicating the 
appropriateness of the nomenclature (Rinderknecht and Humbel, 1978a&b). 
 
The IGF family (Figure 2-1) consists of two peptide ligands (IGF-I and -II), six high-affinity 
IGF binding proteins (IGFBP-1 to -6), two cell surface receptors, the IGF-I receptor (IGF-IR) 
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and the IGF-II/mannose-6-phosphate (M-6-P) receptor (IGF-IIR), and IGFBP proteases (Hwa 
et al., 1999).  
IGF-I is a single chain basic protein of 70 amino acids and IGF-II is a slightly acidic single 
chain-peptide of 67 residues (Rinderknecht and Humbel, 1978a&b). Both peptides are 
ubiquitously expressed and their production is stimulated by a variety of hormones (Sara and 
Hall, 1990).  
IGFs are integral components of multiple systems controlling both growth and metabolism. In 
addition to acting as classical hormones (they circulate in the plasma bound to the IGFBPs), 
they also exert paracrine as well as autocrine effects on cell cycle control and apoptosis (Jones 
and Clemmons, 1995). 
Unlike insulin, circulating IGFs are bound to six IGFBPs, which elicit at least two functions: 
prolongation of the half-life of circulating IGFs and neutralization of their metabolic effects. 
IGFBPs themselves are regulated by protease activity and some may have IGF-independent 
actions. IGFBPs compete with IGF receptors for IGF binding since they have a considerably 
higher affinity for IGFs than the IGF-I receptor (Kelley et al., 1996; Rajaram et al. 1997; Hwa 
et al., 1999). In the circulation, ~75-80% of the IGFs are present in a complex of ~150 kDa, a 
smaller proportion of 20-25% is associated in binary complexes, and less than 1% is found in 
a free form. The ~50 kDa binary complex is made up of several IGFBP species (IGFBP-1 to -
6) that are incompletely saturated with IGFs. The ~150 kDa complex is a ternary complex 
consisting of IGF-I or IGF-II plus IGFBP-3 or -5 and a non IGF binding component, the acid 
labile subunit (ALS) (Rajaram et al., 1997). In addition to the previously mentioned high-
affinity binders, the existence of low affinity binders, such as IGFBP-related proteins and 
proteolysed IGFBPs is known. Contrary to IGFBPs, IGFBP-rPs and IGFBP fragments 
mediate biological effects mainly by IGF-independent mechanisms (Hwa et al., 1999). 
The actions of IGFs are mediated primarily through the IGF-IR. The structurally distinct IGF-
IIR, which is identical to the mannose-6-phosphate receptor (Morgan et al., 1987; Kiess et al., 
1988; Kornfeld, 1992), binds IGF-II with a high affinity and interacts minimally with IGF-I. 
There is no evidence of interaction with insulin (Ballard et al., 1988). This receptor is not 
considered to play a role in IGF signal transduction but it is responsible for clearing and 
thereby reducing the levels of circulating IGF-II. Additionally, the IGF-II receptor plays a 
major role in transporting lysosomal enzymes among intracellular compartments.  
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Figure 2-1: The IGF system (figure adapted from Hwa et al., 1999). The components of 
this system include the peptides IGF-I and -II, IGFBP-1 to -6, IGFBP-rPs, IGFBP 
proteases, IGF-I and -II receptors, and potential IGFBP(s) and IGFBP-rP(s) receptors. 
M6P, Mannose-6-phosphate. ALS, acid-labile subunit. 
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2.1.2 IGF-I 
 
2.1.2.1 IGF-I gene  
 
Since a potential site of regulation of IGF-I function is at the level of biosynthesis, the 
chromosomal localization of its gene is an important first step in understanding the role of 
IGF-I in the etiology of a disease or disorder. The human IGF1 gene is a single copy gene, 
located on the long arm of chromosome 12 (Hoppener et al., 1985). The mouse Igf1 gene is 
located on chromosome ten, whereas the rat Igf1 gene is found on chromosome 7 
(www.ensembl.org).  In humans and rodents, the IGF-I gene spans >80 kb of chromosomal 
DNA and is composed of six exons and five introns (Rotwein, 1991). The expression of IGF-I 
is influenced by hormonal, nutritional, tissue specific, and developmental factors as described 
in chapter 2.1.3.3. 
 
2.1.2.2 IGF-I protein 
 
Through direct amino acid sequencing and by cDNA cloning and DNA analysis the structure 
of IGF-I is known for at least 10 species: 7 mammals (human, bovine, pig, sheep, guinea pig, 
rat, and mouse) and 3 nonmammalian vertebrates (chicken, xenopus, and salmon) (reviewed 
by Rotwein, 1991). The human peptide was the first to be purified and sequenced 
(Rinderknecht and Humbel, 1978a).  
IGF-I is a ~7 kDa single chain polypeptide of 70 amino acids, containing a NH2-terminal B 
domain of 29 residues, a C region of 12 amino acids, an A domain of 21 residues and a 
COOH-terminal D region of 8 amino acids. The IGF-I molecule is evolutionary well-
conserved in vertebrates. There are only 5 amino acid substitutions among the IGF-I 
molecules across 7 different species (Rotwein, 1991). 
 
2.1.2.3 Regulation of IGF-I expression 
 
2.1.2.3.1 RNA 
 
Despite the very simple and compact gene structure, regulation of IGF1 gene expression is 
complicated. In mammals, several transcriptional or posttranscriptional mechanisms, such as 
the use of alternative promoters regulating transcription at multiple initiation sites, differential 
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RNA splicing, and variable RNA polyadenylation are responsible for the production of 
multiple IGF-I mRNA species. Thus, four IGF-I precursor proteins but only a single mature 
70-amino acid IGF-I are produced (Rotwein, 1991; Hall et al., 1992; Rotwein et al., 1993).  
IGF-I expression increases after birth and peaks during the prepubertal years. It is 
predominantly regulated by GH, enhancing its transcription in most tissues but also by other 
hormonal, nutritional, and developmental factors (Salmon and Daughaday, 1957; Roberts et 
al., 1986; Murphy et al., 1987; Mathews et al., 1986; Lowe et al., 1987 and 1988; Daughaday 
and Rotwein, 1989). 
Several investigations revealed that a single injection of GH into GH-deficient 
hypophysectomized rats results in a rapid increase of IGF-I mRNA and thus enhanced levels 
of IGF-I after a few hours with a prompt return to baseline levels (Hynes et al., 1987; Hepler 
et al., 1990; Rotwein et al.1993). First, it was assumed that GH possibly increases IGF-I 
mRNA levels by selective effects on alternative RNA processing (Lowe et al., 1988) but this 
idea turned out to be wrong. Studies in GH-deficient adult rats showed that acute GH 
treatment does not regulate alternative splicing of IGF-I mRNAs, does not lead to preferential 
expression from one of the two IGF-I gene promoters and has no effect on selection of a 
polyadenylation site (Rotwein et al., 1993).  
Additionally to GH, the expression of IGF-I is modulated by other hormones and trophic 
factors. Thyroid hormones were shown to have a modest potentiating effect on GH-stimulated 
IGF-I synthesis (Wolf et al., 1989; Tollet et al., 1990). Studies in isolated rat renal collecting 
ducts demonstrated an enhancement of Igf1 gene expression by the epidermal growth factor 
(EGF) (Rogers et al., 1991). Parathyroid hormone treatment of osteoblast-enriched cultures 
from fetal rat bone causes a small but significant increase of IGF-I mRNA and thus IGF-I 
secretion, whereas treatment with cortisol inhibits this action (McCarthy et al., 1989 and 
1990). Studies in rats showed that estradiol has a dose-dependent effect: acute treatment with 
estradiol profoundly enhances IGF-I mRNA abundance in the uterus, whereas a chronical 
therapy results in inhibition of hepatic IGF-I mRNA and IGF-I serum levels (Murphy and 
Friesen, 1988). 
The nutritional status is an important nonhormonal regulator of IGF-I expression. Fasting of 
rats causes a decline of hepatic IGF-I mRNA and serum IGF-I levels, while refeeding 
neutralizes this effect (Elmler and Schalch, 1987; Straus and Takemoto, 1990). The decrease 
of liver IGF-I mRNA during fasting is mainly regulated at a posttranscriptional level (Zhang 
et al., 1998). 
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Furthermore, the expression of IGF-I is tightly regulated during development. IGF-I is 
essential for normal embryonic growth, as shown in studies of mouse models with a genetic 
ablation of Igf1 as well as in a case study of a boy with a homozygous deletion of the IGF1 
gene (Powell-Braxton et al., 1993; Liu et al., 1993; Baker et al., 1993; Woods et al., 1996). 
On the contrary, the existence of nearly normal size infants with either congenital absence of 
the pituitary or deletions of the genes encoding GH or GH receptors demonstrated that GH is 
not crucial for normal intrauterine development (Le Roith et al., 2001). For example, 
newborns suffering of the Laron syndrome (a hereditary dwarfism resulting from defects in 
the GH receptor gene) are not significantly smaller (42-47 cm) than healthy babies (49-52 cm) 
but show a strong growth retardation during postnatal development (Laron, 2001). The same 
effect is shown in a mouse model for the Laron syndrome (Zhou et al., 1997).  
In the rat IGF-I expression begins well before the developmental onset of GH action and GH 
receptors do not appear in the liver until ~2 weeks after birth (Mathews et al. 1989; Tiong and 
Herington, 1992). Dissimilarly, serum levels of IGF-I increase by nearly 20-fold during the 
first 14 days post natum, reaching 40% of the values found in adult animals (Daughaday et 
al., 1982; Donovan et al., 1991; Kikuchi et al., 1992).  
 
2.1.2.3.2 IGF-I levels in the circulation 
 
Liver-derived IGF-I, mostly regulated by GH, represents the main circulating source of this 
growth factor (Sjogren et al., 1999; Yakar et al., 1999). Circulating IGF-I feeds back centrally 
to inhibit synthesis and release of GH by the anterior pituitary, thus providing a regulatory 
negative feedback loop (Berelowitz et al., 1981; Sheppard and Bala, 1986; Becker et al., 
1995). Studies on rat osteoblasts additionally suggest the presence of a peripheral negative 
feedback loop that allows IGF-I to limit locally the response of extrahepatic tissues to 
circulating GH (Leung et al., 1996). 
In the circulation, most of the IGFs form binary complexes with one of the IGFBPs or ternary 
complexes with IGFBP-3 or -5 and ALS, acting as classical hormones (for further details see 
chapter 2.1.6).  
Studies of IGF-I levels in healthy children showed that serum levels of IGF-I are only 50 % of 
adult values at birth and rise gradually during childhood to reach a peak at puberty, being at 
this point 2-3 fold higher as compared to average adult values. After puberty the levels slowly 
decline with age (Hall et al., 1980; Luna et al., 1983; Silbergeld et al., 1986; Yu et al., 1999b). 
The described rise and fall of IGF-I levels in circulation during and after teenage years is due 
Review of the literature 
__________________________________________________________________________________________ 
9
to an increased secretion of GH during puberty and a decreased release afterwards (Mauras et 
al., 1987; LeRoith et al., 1992).  
 
2.1.2.4 Biological effects of IGF-I 
 
2.1.2.4.1 Overview 
 
IGFs are integral components of multiple systems controlling both growth and metabolism. In 
addition to endocrine effects exerted by circulating IGFs, locally produced IGFs exert 
paracrine as well as autocrine effects on cell cycle control and apoptosis, two functions also 
involved in tumorigenesis (Jones and Clemmons, 1995).  
The most widely studied effect of the IGFs in vitro is the stimulation of DNA synthesis and 
cell replication, particularly using BALB/c-3T3 cells (mouse fibroblasts) for these 
experiments. IGF-I has been shown to function as a progression factor in the cell cycle by 
stimulating cells to traverse its successive phases. Moreover, it has been demonstrated that 
more than one growth factor is required for optimal growth in normal cells, since IGF-I could 
only elicit its effects after the cells had been primed with PDGF (Baserga and Rubin, 1993; 
Pardee, 1989). Apart from fibroblasts, IGF-I stimulates a mitogenic response in a wide variety 
of cells such as chondrocytes, osteoblasts, keratinocytes, thyroid follicular cells, smooth 
muscle cells, skeletal muscle cells, neuronal cells, mammary epithelial cells, mesangial cells, 
erythroid progenitor cells, thymic epithelium, oocytes, granulosa cells, spermatogonia, Sertoli 
cells and several cancer cell lines, showing enhanced proliferation after IGF-I treatment (for 
reviews see Lowe, 1991; Sara and Hall, 1990; Giudice, 1992; Mcauley, 1992; Cohick and 
Clemmons, 1993; Jones and Clemmons, 1995). 
IGF-I also acts as a survival factor due to its capacity to inhibit apoptosis in certain cells (Sell 
et al., 1995; Parrizas et al., 1997; Ferrari et al., 1998). Additionally, the IGFs are known to 
promote differentiation of cells, such as myoblasts, osteoblasts, osteoclasts, chondrocystes, 
neural cells, and adipocytes (Florini and Magri, 1989; Mochizuki et al., 1992; Geduspan and 
Solursh, 1993; Pahlman et al., 1991; Sara and Hall, 1990).  
Furthermore, the IGFs regulate the hormone secretion of many cell types. Hormone synthesis 
and secretion of ovarian granulosa and theca cells is stimulated by both insulin-like growth 
factors, whereas the thymulin secretion by thymic epithelium and the hormone secretion from 
Leydig cells and thyroid follicular cells are only stimulated by IGF-I (Giudice, 1992; Timsit 
et al., 1992; Lowe, 1991). IGF-I treatment on adrenal fasciculata cells increases the number of 
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adrenocorticotropic hormone (ACTH) receptors and potentiates steroid hormone secretion in 
response to ACTH (Penhoat et al., 1989). 
In vivo actions of IGF-I have been studied by administration of this peptide to several animal 
species and humans, as well as in IGF-I knockout or overexpressing animal models. A short 
summary of the effects of administrated IGF-I observed in normal humans volunteers is 
shown in table 2-1. The observed effects are comparable to the effects seen in rats (reviewed 
in Jones and Clemmons, 1995). 
Biological effects of IGF-I in various genetically engineered mouse models are described in 
chapter 2.2. 
 
            Table 2-1: Effects of IGF-I administration to humans (table from Jones and Clemmons, 1995). 
 
 
Function 
 
IGF-I effect 
 
Glucose metabolism 
 
↑ Glucose uptake 
↓ Hepatic glucose production (human) 
↑ Apparent insulin sensitivity 
Hypoglycemia (esp. with i.v. administration) 
 
Fat metabolism ↓ Serum ketones  
↓ Serum free fatty acids (human) 
↓ Triglycerides 
 
Protein metabolism ↑ Protein synthesis 
↓ Nitrogen excretion 
↑ Total body protein accretion 
↑ Body/organ weight, esp. spleen, thymus, kidney 
Improved wound heeling 
 
Renal function ↑ Glomerular filtration rate 
↑ Renal plasma flow 
↑ Speed of recovery from ischemic acute renal failure 
 
Counterregulatory hormones ↓ GH 
↓ Glucagon 
↑ Catecholamines 
 
Linear Growth ↑ In hypopituitary and GH-insensitive subjects 
 
Miscellaneous side effects Partoid enlargement and tendeness, headache,  
peripheral edema, tachycardia 
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2.1.2.4.2 Growth and development 
 
IGF-I plays an important role in both embryonic and postnatal growth. Homozygous IGF-I 
knockout mice are born small (60 % of normal weight) and grow very poorly postnatally 
(Powell-Braxton et al., 1993; Baker et al., 1993; Liu et al., 1993). In contrast, lines of mice 
selected for high serum IGF-I levels show increased body weight (Blair et al., 1988). The idea 
of a GH-independent effect of IGF-I in embryonic growth is strongly supported by studies of 
GH and GH-receptor gene-deleted mice having relatively normal birth weights (Le Roith et 
al., 2001).   
Generation of liver-specific IGF-I deficient mice (LID mice) demonstrated that the liver is the 
principal source of IGF-I in the circulation. In these mice, the concentration of IGF-I in the 
serum was reduced by 75%. Interestingly, the reduction of serum IGF-I concentration had no 
effect on postnatal body growth, indicating that autocrine/paracrine-produced IGF-I is more 
important than liver-derived IGF-I for body growth (Sjogren et al., 1999; Yakar et al., 1999).  
In humans, circulating IGF-I levels also correlate with body size: constitutional tall children 
and adolescents have elevated levels (Gourmelen et al., 1984), whereas pygmy populations in 
Africa and from the Philippines display significantly decreased levels of this peptide 
(Baumann et al., 1989; Davila et al., 2002). Moreover, the description of a 15-year old patient 
carrying a homozygous partial deletion (exon 4 and 5) of the IGF1 gene resulting in serum 
IGF-I levels below detection level demonstrated that IGF-I is also important for human fetal 
growth. This mutation was manifested with severe intrauterine and postnatal growth failure, 
sensorineural deafness and mild mental retardation (Woods et al., 1996). Recently, a new 
patient carrying a mutation in the IGF1 gene was reported. Again pre- and postnatal growth 
failure and sensorineural deafness were the main clinical findings (Bonapace et al., 2003). 
As a result of selective breeding, the domestic dog shows a very high degree of variation in 
body size. Evaluation of plasma IGF-I concentrations and comparison with body size in giant 
and miniature dog breeds revealed that these two parameters highly correlate (Eigenmann et 
al., 1988).  
 
2.1.2.4.3 Bone metabolism 
 
The mammalian skeleton (uniquely designed for its protective and structural roles) is a highly 
organized and physiologically active organ, consisting of an outer surface of cortical bone 
surrounding the inner trabecular elements. The trabecular skeleton is bathed in marrow, 
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whereas the cortical bone is nourished by perostial vessels and a series of canaliculi. The 
latter connect osteocytes to lining cells and osteoblasts. To preserve the integrity of the 
skeleton, both cortical and trabecular bone continuously undergo remodeling processes 
(Yakar and Rosen, 2003).   
The IGF system is thought to play an important role in bone physiology, since several 
components of this system (IGF-I and -II, IGFBP-1 to -6, and IGFBP proteases) are stored 
abundantly in the skeletal matrix. Additionally, the IGF-IR is present in both osteoblasts and 
osteoclasts. During bone resorption the IGFs are released from storage, and in combination 
with circulating IGFs, influence the action of osteoblasts and osteoclasts during the process of 
remodeling (Yakar and Rosen, 2003). Liver-derived IGF-I, the main source of circulating 
IGF-I, is known to be critical for the modeling of bone, particularly cortical perostial bone 
growth, but is not required for the maintenance of trabecular bone in adult mice (Sjogren et 
al., 2002; Yakar et al., 2002). 
Studies of genetically altered mouse models demonstrated that IGF-I has a great impact on 
longitudinal bone growth, perostial circumference, and bone mineral density (BMD). IGF-I 
deficient mice are significantly smaller compared to their wildtype littermates. Powell-
Braxton et al. (1993) observed no histopathological difference in bone development, whereas 
the IGF-I deficient mice generated in the lab of Argiris Efstradiadis displayed smaller bones 
and delayed ossification (Liu et al., 1993; Baker et al., 1993). Further studies revealed a 
reduction in the size of hypertrophic chondrocytes in the proximal growth plate of the tibia 
and the distal femur. It is assumed that a decreased rate of production and maturation of 
hyperthropic zone chondrocytes leads to a significant reduction in the height of the spongiosa 
and thus to shorter bones in IGF-I deficient mice (Lupu et al., 2001). Bikle et al. (2001) 
showed a reduction of tibial bone formation rate and cortical thickness in homozygous IGF-I 
knockout mice. Interestingly, the trabecular bone volume (bone volume / total volume) is 
increased in the previously mentioned mice, showing a strong interaction with gender: male 
mice display a 23% and females an 88% higher value compared with wildtype controls as a 
result of increased connectivity, increased number and decreased spacing of the trabeculae. 
Furthermore, it was demonstrated that IGF-I in particular influences the increase of BMD 
during puberty. Deletion of the Igf1 gene completely prevented perostial expansion during 
teenage years and the peak BMD was significantly reduced (Mohan et al., 2003). In 
accordance with this data, overexpression of IGF-I in osteoblasts increased peak BMD (Zhao 
et al., 2000). 
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2.1.2.4.4 Cancer 
 
There is a lot of experimental evidence supporting a role for the insulin-like growth factor 
signaling system in the progression and maintenance of cancer. Moreover, the differential 
expression of its components in tumors relative to normal tissues makes this system an 
attractive target for therapeutic intervention (reviewed by Foulstone et al., 2005).  
A correlation between circulating levels of IGF-I and IGFBP-3, and the relative risk of 
developing colon, breast, prostate, and lung cancer has been shown in various human 
epidemiological studies (Ma et al., 1999; Hankinson et al., 1998; Chan et al., 1998; Wolk et 
al., 1998; Yu et al., 1999a; Giovannucci et al., 2000). It is not only suggested that individuals 
with circulating levels of IGF-I at the high end of the normal range are more prone to develop 
certain cancers, but it is also suggested that IGF-I signaling stimulates growth of established 
cancers (Pollak, 2004). This hypothesis is supported by studies of mouse models (LID mice), 
in which circulating IGF-I levels are reduced, while tissue expression of IGF-I is normal. 
When compared with control mice, these mice show a lower risk for the development of 
colon and breast cancers and metastases (Yakar et al., 2004; Wu et al., 2002; Wu et al., 2003). 
Studies of another mouse model, the transgenic adenocarcinoma of mouse (TRAMP) 
corroborates the importance of IGF-I during the initiation and progression of primary prostate 
cancer (Kaplan et al., 1999).  
 
2.1.3  IGF-II 
 
2.1.3.1 IGF-II gene  
 
The human IGF2 gene spans 30 kb of chromosomal DNA on the distal short arm of 
chromosome 11. It consists of nine exons and has four promoters (Holthuizen et al., 1993; 
Sussenbach et al., 1993).  
In rodents, the 12 kb spanning Igf2 gene consists of six exons and has three promoters. The 
mouse Igf2 gene is located on chromosome 7, whereas the rat Igf2 gene is found on 
chromosome 1 (Rotwein and Hall, 1990; Soares et al., 1986). The IGF2 genes of all three 
species form a linkage group regarding the position of the insulin gene, indicating that the 
IGF2/insulin locus was present prior to the mammalian radiation (Rotwein and Hall, 1990).  
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2.1.3.2 Parental imprinting 
 
Genomic (or parental) imprinting is a phenomenon which leads to selective modification of 
specific genetic loci during the development and differentiation of the male and female 
germlines, and results in differential expression of these genes depending on their parental 
legacy (reviewed by Solter, 1988; Surani et al., 1990; Cattanach and Beechey, 1990).  
Using a mouse model that carried a targeted disruption of Igf2, it could be shown that 
transmission of the mutation through the male germline resulted in growth-deficient 
heterozygous progeny. In contrast, the heterozygous offspring was phenotypically normal 
when the disrupted gene was transmitted maternally. Molecular analysis revealed that only 
the paternal allele is expressed in embryos, while the maternal is silent. Only the choroid 
plexus and the leptomeninges were excluded from the otherwise general influence of 
imprinting on IGF-II expression (DeChiara et al., 1991). Furthermore, genetic imprinting of 
the IGF2 gene has been clearly demonstrated in rats and humans. In the latter, the existence of 
a promoter-specific imprinting status is indicated since in the adult liver IGF-II expression is 
biallelic and solely derived from P1 (also see chapter 2.1.4.4.1) (Holthuizen et al., 1999). 
Relaxation or loss of IGF2 gene imprinting, resulting in biallelic expression, occurs in the 
Beckwith-Widemann syndrome of somatic overgrowth, sporadic Wilms’ tumor and several 
other cancers (O’Dell and Day, 1998). 
 
2.1.3.3 IGF-II protein 
  
The mature IGF-II peptide is a slightly acidic ~7 kDa 67 residue molecule, containing a NH2-
terminal B domain of 28 amino acids, a C domain of 12 residues, an A region of 21 amino 
acids, and a COOH-terminal D region of 6 amino acids (Rotwein, 1991). Like the IGF-I 
protein, it is highly conserved among different species and its sequence is known for at least 
10 mammalian and 6 nonmammalian species. Interestingly, several human IGF-II proteins, 
such as a 69- or 70-amino acid IGF-II peptide, have been characterized but their biological 
significance is unknown. It is assumed that this observation is due to allelic variation in the 
IGF2 gene, since the DNA sequence alteration responsible for the new amino acids does not 
occur near an intron-exon junction (Rotwein, 1999). 
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2.1.3.4 Regulation of IGF-II expression 
 
2.1.3.4.1 RNA 
 
Similarly to the IGF1 gene, the gene encoding IGF2 is a complex transcription unit, where 
multiple mRNAs are synthesized as a result of alternate promoter usage and alternative RNA 
polyadenylation (Rotwein, 1991). As previously mentioned, the human IGF2 gene consists of 
nine exons (E1-9), of which E1-6 are non-coding leader exons, whereas E7, 8 and the first 
part of E9 code for the IGF-II precursor protein (Sussenbach et al., 1994). The rodent Igf2 
genes consist of six exons (E1-6): E1-3 are non-coding leader exons and E4-6 code for the 
IGF-II precursor protein (Rotwein and Hall, 1990; Holthuizen et al., 1993). The expression of 
the gene is developmentally regulated. The human IGF2 gene is transcribed by four different 
promoters (P1 to P4). P1 is exclusively activated in adult liver tissues, whereas P3 is the most 
active promoter in fetal tissues. In fetal liver P2-P4 are active but they are shut off at birth. 
The major human promoters active in non-hepatic adult tissues are P3 and P4 (Holthuizen et 
al., 1993).  
There are homologous promoters for human P2, P3 and P4 in mouse and rat, whereas a 
homologue for P1 is absent. In mice and rats, expression of IGF-II is shut down in almost 
every tissue shortly after birth and is believed to be a consequence of the lack of a homologue 
to human P1 (Holthuizen et al., 1993). During adult live IGF-II expression is maintained only 
in the exchange tissues of the brain (Stylianopoulou et al., 1988; Lee et al., 1990; DeChiara et 
al., 1991). 
The expression of IGF-II is regulated at multiple levels: tissue-specific and developmental 
stage dependent transcription initiation, alternative splicing, usage of multiple 
polyadenylation sites, site-specific endonucleolytic cleavage of IGF-II mRNAs, and 
translational control (Sussenbach et al., 1989).  
Hormonal regulation of IGF-II expression has been shown in several cases but their 
mechanisms of actions or the identification of specific responsive elements, which may be 
involved in regulation, are still elusive. Moreover, species differences seem to play an 
important role (reviewed in Holthuizen et al., 1999). 
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2.1.3.4.2 IGF-II levels in the circulation 
 
In humans, circulating levels of IGF-II are low at birth and increase with age until puberty to 
remain at steady levels afterwards. The gender difference (only 2%) is minimal (Yu et al., 
1999). In mice and rats, circulating IGF-II levels rapidly fall after birth and only very low 
levels are detectable throughout adult life, reflecting the expression pattern (Soares et al., 
1985; Murphy et al., 1987; Rotwein et al., 1988; Wilson et al., 1987; Bautista et al., 1990; 
Ren-Qiu et al., 1993). Similar to IGF-I, most of the circulating IGF-II is bound in binary and 
ternary complexes (Rajaram et al., 1997). 
IGF-II levels in the circulation are dependent on GH but this only becomes apparent at 
subnormal growth hormone levels as shown in studies of normal subjects and patients with 
growth disorders. GH deficiency leads to significantly decreased IGF-II levels, whereas 
oversecretion of GH does not increase the values of this peptide. It is assumed that normal 
GH levels already stimulate IGF-II production maximally (Zapf et al., 1981). 
 
2.1.3.5 Biological effects of IGF-II 
 
In vitro studies of mouse embryos from the 1-cell to the 64-cell stage demonstrated that IGF-
II, but not IGF-I and insulin transcripts, are expressed before implantation (Rappolee and 
Werb, 1991). Additionally, supplementation of culture medium with recombinant IGF-II 
stimulates growth and metabolism of early mouse embryos (Harvey and Kaye, 1992). 
IGF-II is known to be an important regulator of embryonic growth and differentiation, which 
has been elegantly demonstrated by DeChiara and colleagues, (1990), who showed that mice 
bearing a disrupted IGF-II allele display marked growth retardation. IGF-II deficient mice are 
only 60% of weight compared to their wildtype controls. During embryonic development the 
growth effects of IGF-II occur earlier than IGF-I effects. Subsequent analysis of mouse 
fetuses lacking expression of IGF-I, -II or IGF-IR revealed that IGF-II interacts with the IGF-
IR from embryonic stage 11 to 12.5 onwards and with a second receptor, the insulin receptor, 
from embryonic day 13.5 onwards. At this stage, IGF-I comes into play as a stimulator of 
embryonic growth (Liu et al., 1993; Baker et al., 1993; Louvi et al., 1997).  
 
Whilst IGF-II has a clearly established role in embryonic and fetal development, its role in 
postnatal life remains poorly understood. Similar to IGF-I, IGF-II has proliferative and 
antiapoptotic actions since its effects are exerted by the IGF-IR (Stewart and Rotwein, 1996). 
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Studies of prepubertal children with a constitutionally tall stature (CTS) demonstrated 
significantly increased serum IGF-II levels compared to their control groups, whereas the 
secretory state of GH was normal and serum levels of IGF-I, IGFBP-3 and ALS were not 
significantly altered. The increased IGF-II levels involve a significantly higher IGF/IGFBP 
molar ratio and, therefore, an increase in the potentially bioactive free form of the IGFs. 
These findings lead to the assumption that high circulating levels of IGF-II might be 
responsible for increased growth velocity, especially in early childhood, when the still 
immature GH-IGF-I axis has not yet fully assumed its predominat role in body growth 
(Garrone et al., 2002). 
Furthermore, overexpression of IGF-II has been frequently observed in a variety of human 
malignancies such as breast, prostate, and colon cancer. Also, it is constantly found in 
pediatric cancers, like Wilms’ tumor and rhabdomyosarcoma. IGF-II expression leads to an 
autocrine feedback loop stimulating the IGF-IR to stimulate cancer cell proliferation. In 
certain large tumors, particularly fibrosarcomas, rhabdosarcomas, and leimyosarcomas, the 
production of IGF-II may result in tumor-associated hypoglycemia (reviewed in Stewart and 
Rotwein, 1996; Le Roith and Butler, 1999; Moschos and Mantzoros, 2002). 
To elucidate the effects of postnatal elevated IGF-II several mouse models overexpressing 
this peptide have been generated as detailed described in chapter 2.3. These models 
demonstrated that postnatal overproduction of IGF-II positively affects body and organ 
weights but has no effect on body growth. Only the mouse models with the highest transgene 
expression suffer from hypoglycemia, whereas moderate IGF-II expression does not lead to a 
decrease in serum glucose levels. Tumor formation has also only been observed in the mouse 
models with the highest IGF-II expression. Moreover, the different malignancies occurred 
after a very long latency and not all organs exposed to high concentrations of this peptide 
developed tumors (reviewed by Wolf et al., 1998). As shown in a study of transgenic mice 
overexpressing the simian virus-40 large T-antigen under the control of the insulin promoter 
strongly, it is very likely that IGF-II works as a second signal, maintaining the proliferation of 
neoplastic cells and is not a causative agent for tumor development (Christofori et al., 1994). 
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2.1.4 The IGF receptors 
 
2.1.4.1 IGF-I receptor (IGF-IR) 
 
The IGFs elicit their effects through activation of a specific high affinity cell-surface receptor, 
the insulin-like growth factor I receptor (IGF-IR). In structure and signaling, the IGF-IR is 
closely related to the insulin receptor, with greater than 50% overall amino acid homology. 
IGF-IR is a heterotetrameric glycoprotein composed of two α- and two β-subunits joined by 
disulfide linkages (Abbot et al., 1992). The α-subunit, containing 706 amino acids, is totally 
extracellular and mainly involved in ligand binding. The β-subunit, containing 627 amino 
acids, is composed of a short extracellular domain, a membrane spanning segment, and a 
large intracytoplasmatic region including a tyrosin kinase domain (Stewart and Rotwein, 
1996). However, the IGF-IR is not a unique molecular entity. There is a large degree of 
heterogeneity that can be explained by a number of mechanisms, including potential primary 
structure variation, differential glycosylation, and hybrid formation with insulin receptors 
(Blakesley et al., 1999). 
Ligand binding to the α-subunit initiates a conformational change that is transmitted to the 
intracellular domain leading to receptor autophosphorylation on several tyrosine residues by 
an intramolecular transmechanism. After autophosphorylation, the receptor is fully active as a 
tyrosine kinase towards endogenous substrates. Activation of IGF-IR triggers intracellular 
events that regulate the cell cycle, apoptosis, cellular motility and gene expression (De Meyts 
et al., 1994).  
The IGF-IR binds IGF-I and IGF-II with a high affinity (~10-10 M) and insulin with a strongly 
(100-fold) lower affinity (Blakesley et al., 1996). This high affinity binding is dictated by the 
primary sequence of both the ligand and the receptor. Furthermore, the binding of IGFs to the 
IGF-I receptor is modulated by specific IGF- binding proteins (IGFBPs) (Blakesley et al., 
1996). 
The human IGF-IR protein is produced by mRNAs derived from the single 21-exon IGF1R 
gene, located on chromosome 15 (Abbot et al., 1992). The IGF1R gene is not subjected to 
parental imprinting (Liu et al., 1993). Expression levels of the IGF-IR are maximal at prenatal 
stages and decrease subsequently during postnatal development (Werner et al., 1989).  
Genetic inactivation of the IGF-IR by targeted disruption of the Igf1R gene causes severe 
neonatal growth deficiencies as a consequence of hypoplasia in several tissues. Mice lacking 
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the Igf1R gene are only 45% of normal size and die shortly after birth because of respiratory 
failure (Liu et al., 1993). 
 
2.1.4.2 IGF-II receptor (IGF-IIR) 
 
The second receptor of the IGF system is the structurally distinct IGF-II receptor (IGF-IIR), 
which is identical to the mannose-6-phosphate receptor (Morgan et al., 1987; Kiess et al., 
1988; Kornfeld, 1992). This single-chain membrane-spanning glycoprotein is devoid of 
tyrosin kinase activity. At present, there is no evidence for signal transduction mediated 
through the IGF-IIR (Stewart and Rotwein, 1996; Nissley, 1999). 
The mature human IGF-IIR, containing 2,451 amino acids, can be divided into three regions: 
a large 2,264-residue extracellular domain, a 23-amino acid transmembrane region, and a 164-
residue carboxyl-terminal intracytoplasmic domain (Morgan et al., 1987; Oshima et al., 
1988). The extracellular domain is responsible for ligand binding, whereas the 
intracytoplasmatic region regulates movement among different cellular compartments 
(Stewart and Rotwein, 1996). The IGF-II receptor binds IGF-II with a high affinity but 
interacts minimally with IGF-I and not at all with insulin (Ballard et al., 1988). Binding and 
internalization of IGF-II at the cell surface result in degradation of this ligand. Thus, the IGF-
IIR is able to regulate the IGF-II action by growth factor clearance (Kiess, 1999). 
Harboring two functionally distinct carbohydrate recognition domains, the IGF-IIR is able to 
bind lysosomal enzymes and other proteins bearing a mannose-6-phosphate recognition 
sequence. Therefore IGF-IIRs play an important role in the clearance of lysomal enzymes 
from their extracellular environment (Marron-Terada et al., 1998; Marron-Terada et al., 
2000).  
The IGF-IIR is also found in the circulation, cleaved from the cell surface receptor. 
Particularly in the foetal plasma it binds a significant amount of IGF-II and may function as 
an IGF-II-specific binding protein (Gelato et al., 1989). 
The IGF-IIR is highly conserved among different species, with ~80% identity being found 
among bovine, rat, mouse, and human receptors (Kornfeld, 1992; Stewart and Rotwein, 
1996). In humans the IGF2R gene is located on chromosome 6 (Laureys et al., 1988). In mice, 
the Igf2R gene resides in the proximal region of chromosome 17 and is closely linked to the 
T-associated maternal effect (Tme) locus (Barlow et al., 1991; Szebenyi and Rotwein, 1994; 
Ludwig et al., 1996). Since genetic imprinting of this gene occurs in mouse and rats, but not 
in humans (Mills et al., 1998; Treacy et al., 1996), it provides one plausible explanation for 
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the enhanced sensitivity of mice to tumor formation (De Souza et al., 1997). Interestingly, 
opposite to IGF-II, the IGF-IIR is imprinted maternally (Barlow et al., 1991).  
Genetic inactivation of the IGF-IIR by gene targeting results in fetal overgrowth, skeletal 
abnormalities and perinatal death due to overexposition of fetuses to IGF-II (Wang et al., 
1994; Lau et al., 1994; Ludwig et al., 1996).  
  
2.1.5 The IGF-binding proteins (IGFBPs) and  the acid-labile subunit (ALS) 
 
The insulin-like growth factor binding proteins (IGFBPs) comprise a family of six structurally 
and evolutionary related peptides (IGFBP-1 to IGFBP-6), which are expressed in a tissue 
specific manner and have different affinities for the IGFs. They are present in different 
concentrations in different body compartments and they can modulate the different IGF 
actions both positively and negatively. IGFBPs compete with IGF receptors for IGF binding 
since they have much higher affinities for IGFs (kd ~10-10 M) than the IGF-I receptor (kd  ~10-
8-10-9 M). Through this binding they form binary ~50 kDa complexes with the IGFs (Kelley 
et al., 1996; Rajaram et al. 1997; Hwa et al., 1999). 
In circulation, ~75-80% of the IGFs are present in a complex of ~150 kDa, a smaller 
proportion of 20-25% is associated in ~50 kDa binary complexes, and less than 1% is found 
in form of ~7.5 kDa. The ~150 kDa complex is a ternary complex comprising of one 
molecule of IGF, IGFBP-3 or -5 and an 85kDA glycoprotein, the acid labile subunit (ALS) 
(Rajaram et al., 1997).  However, the contribution of IGFBP-5 to the circulating ternary 
complex appears to be smaller compared to that of IGFBP-3 (Baxter et al., 2002). 
ALS, mainly synthesized in the liver, is predominantly stimulated by the growth hormone 
(GH).  Since the onset of ALS synthesis is one of the last events in the development of the 
circulating IGF system, high serum levels are almost exclusively found postnatally (Boisclair 
et al., 2001). 
In adult animals, serum IGFs reach concentrations that are ~1000 fold that of insulin. ALS is 
a critical component  that contributes to the development of this large reservoir by extending 
half-lives of IGFs from 10 minutes when in free form, and 30-90 minutes when in binary 
complexes, to more than 12 hours when bound in ternary complexes (Guler et al., 1989; Zapf 
et al., 1995). 
A second important role of ALS, considering this large reservoir of bioactive IGFs in the 
circulation, is the prevention of non specific metabolic effects of the IGFs such as 
hypoglycemia. In contrast to free IGFs and IGFs bound to a ~50 kDa binary complex, the 
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~150 kDa complexes cannot traverse capillary endothelia and activate the insulin receptor 
(Zapf et al., 1995).  
For their actions on target cells specific mechanisms must exist to release IGFs from ternary 
complexes. At least three mechanisms have been shown to alter the affinity of IGFBPs to 
IGFs, thus as: IGFBP proteolysis, phosphorylation, and adherence to the cell surface or to 
extracellular matrix (Clemmons, 1997). 
IGFBPs have also been reported to be able to exert IGF-independent effects. To determine the 
in vivo significance of data, obtained using in vitro culture systems, several mouse models 
have been generated and investigated. 
Further information about transgenic and knockout mice experiments for IGFBPs and ALS 
can be found in comprehensive reviews (Schneider et al., 2000; Boisclair et al., 2001; Silha 
and Murphy, 2002; Wolf et al., 2005). 
 
2.1.6 The IGF-binding protein-related proteins 
 
The discovery of several groups of cysteine-rich proteins sharing important structural and 
functional similarities with the IGFBPs has led to the proposal of an IGFBP superfamily, 
comprised of the IGFBPs and the IGFBP-related proteins (IGFBP-rPs) (Bork, 1993; Oh et al., 
1996; Kim et al., 1997; Hwa et al., 1999). IGFBP-rPs bind IGFs but with substantially lower 
affinity than is the case with IGFBPs. It is most likely that IGFBP-rPs mediate biological 
effects mainly by IGF-independent mechanisms and may also act through IGF-dependent 
mechanisms (Hwa et al., 1999). Their activities are not very well understood but they may be 
important regulators of IGF functions and are object of intense research.  
 
2.2  Genetically engineered mouse models for IGF-I and IGF-II 
 
2.2.1 Overview 
 
In order to study biological activities in vivo the mouse has been of particular interest among 
scientists from a wide range throughout the 20th century. This is due to its close genetic and 
physiological similarities to humans as well as to the ease with which its genome can be 
manipulated and analyzed.  In the early days, biological studies involving alteration the 
mouse genome had to rely either on the appearance of spontaneous mutations or on the 
generation of chemically- and radiation-induced mutations and allophenic mice. Although 
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these studies played a major role in biomedical research, they are not without disadvantages. 
While spontaneous mutations are rare events, physical and chemical mutagenesis has an 
entirely random character and identification and characterization of the mutations are very 
time consuming. In the late 1980s, the merging of recombinant DNA methods with 
mammalian cell culture and embryo manipulation techniques provided a great breakthrough 
in biomedical research. Two new genetic technologies allowed producing custom-made 
mouse models. The first approach, transgenesis, consists in inserting foreign gene products in 
the mouse chromosomes to produce gain-of-function mutants. In the second approach, gene 
targeting, endogenous genes are disrupted, with results ranging from subtle mutations to 
complete loss of gene function (loss-of-function mutants). The former animals are called 
transgenic and the latter knockout mice (Jonas, 1984; Hafner and Müller, 2004).  
 
To gain insight into the functions of IGF-I and -II during embryogenesis and postnatal 
development transgenic and knockout mice models have been established for both peptides 
(reviewed by Efstratiadis, 1998). IGF-I deficient and IGF-II transgenic mice are described in 
detail in chapters 2.2.2 and 2.2.3.  
The investigation of IGF-I transgenic mice carrying human IGF-I coding sequences fused to 
the mouse metallothionein I promoter revealed that chronically elevated levels of IGF-I led to 
an increase in body weight as a result of selective organomegaly without an apparent increase 
in skeletal growth. Carcass weights are proportionally increased to body weight and also the 
spleen, pancreas, brain, and kidney exhibited significant overgrowth (Mathews et al., 1988; 
Quaife et al., 1989). Further studies showed that small bowel length and mass are greater in 
IGF-I transgenic mice compared to wildtype littermates (Ohneda et al., 1997). Overexpression 
of IGF-I was also targeted to specific tissues. For instance, constantly elevated levels of IGF-I 
in the heart are coupled with myocte proliferation in transgenic mice (Reiss, et al., 1996) and 
overexpression of IGF-I in the epidermis induces hyperplasia, dermal abnormalities, and 
spontaneous tumor formation (Bol et al., 1997). In the latter model, transgenic mice develop 
squamous papillomas (some of which converted to carcinomas) in a significant proportion 
compared to non-transgenic littermates (DiGiovanni et al., 2000). 
IGF-II deficient mice are born with only 60% of normal weight but do not display further size 
reduction and have ~60% of normal weight at steady state. Otherwise they appear normal and 
are fertile. These results suggest that IGF-II is only essential for normal embryonic growth 
(DeChiara et al., 1990). 
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2.2.2 IGF-I deficient mice 
 
In 1993, two independent laboratories generated IGF-I deficient mice by homologous 
recombination in embryonic stem cells. Powell-Braxton and collaborators created IGF-I 
deficient mice by inserting a neomycin gene at amino acid 15 of the major protein. 
From birth on, heterozygous IGF-I deficient mice, displaying serum IGF-I levels 37% lower 
than normal, are 10- 20% smaller than their wildtype littermates and the size difference 
continues throughout growth. The size reduction is due to a decrease in organ, muscle, and 
bone mass in the absence of histological abnormalities. Both sexes are healthy and fertile and 
can be used for intercrossing to generate homozygous IGF-I deficient mice. 
At birth, homozygous IGF-I deficient mice have only ~60% of the body weight of their 
wildtype siblings and the majority (>95%) dies perinatally, showing atelectatic lungs. The 
absolute size of homozygous knockout and wildtype mice is variably depending on the 
genetic background and litter size. Histopathological studies of embryonic mice and neonates 
revealed that the homozygous IGF-I knockouts display an underdevelopment of muscle tissue 
and that the lungs are less organized with ill-defined alveolae. No histopathological 
differences in bone development between these two groups can be found (Powell-Braxton et 
al., 1993). 
The laboratory of Argiris Efstradiadis generated IGF-I deficient mice, using a slightly 
different strategy (insertion of the neomycin gene at amino acid 50). Although the overall 
phenotype is comparable, their mice do not seem to be so severely compromised. 
Heterozygous IGF-I deficient mice do not show any obvious phenotypic difference from 
wildtype siblings (Liu et al., 1993).  
Homozygous IGF-I knockouts, showing a serum level of IGF-I beyond detection level, are 
also ~60% of normal birth weight. Although some of the dwarfs die shortly after birth, they 
are all able to breathe. Neonatal death occurs between 15 minutes and 6 hours after birth, for 
unknown reasons. Notably the survival rate depends on the genetic background (Liu et al., 
1993). Studies of postnatal growth revealed that their relative size decreases progressively 
from 60% of normal birth weight to about 30% of the weight of their wildtype littermates at 
an age of 8 weeks, thereafter remaining at this level. Despite this highly decreased body 
weight, the homozygous IGF-I knockout mice appear proportionate in size and behave 
normally. Examination of the progress of long bone ossification in adult homozygous IGF-I 
deficient mice showed that it proceeds with a greatly reduced rate (Baker et al., 1993). 
Moreover, both sexes of these dwarfs do lack libido and are infertile. Female mutants possess 
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an infantile uterus exhibiting a strong hypoplasia especially in the myometrium. The primary 
cause of their infertility is thought to be their failing to ovulate even after administration of 
gonadotropins. Male mutants show reduced testes size and have only 18% of the normal level 
of spermatogenesis. Vas deferens of the epididymal duct, seminal vesicles and prostate are 
vestigial. Since capacitated sperms are able to fertilize wildtype eggs in vitro, the primary 
cause of infertility is thought to be the drastically reduced level of testosterone, resulting in a 
failure of androgenization and thus absence of mating behavior (Baker et al., 1996).  
 
2.2.3 IGF-II transgenic mice 
 
To elucidate the function of IGF-II in postnatal life, several mouse models overexpressing this 
growth factor have been generated over the last decades. Therefore, sequences coding human 
or mouse IGF-II have been placed under the transcriptional control of promoter elements 
from different genes, e.g. the mouse major urinary protein (MUP) gene, the bovine keratin 10 
gene (BKVI), the mouse H-2Kb gene, or the rat phosphoenolpyruvate carboxykinase (PEPCK) 
gene (reviewed in Wolf et al., 1998). In MUP-IGF-II transgenic mice the tissue specific 
expression of the transgene starts 3 to 4 weeks after birth and can be detected in the liver, the 
preputial glands, and low in the adrenal glands. Serum IGF-II levels are ~30-fold higher 
compared to controls. Adult transgenic mice are smaller than their controls and have a 
significantly reduced body weight. The fat mass is reduced between 44 and 77%, being the 
major cause of the low body weight and fat mass. Also, their lean body mass is reduced. 
Transgenic animals develop hypoglycemia and hypoinsulinemia and show an incidence for a 
diverse spectrum of different tumors after a long latency (Rogler et al., 1994).  
BKVI-IGF-II transgenic mice show transgene expression in skin, duodenum, ileum, appendix, 
colon, and uterus from embryonic stage 16.5 onwards. Serum levels are ~2- 4-fold higher 
compared to wildtype controls. Transgenic animals exhibit an overgrowth of skin and 
increased weights of appendix, colon, and uterus. They are leaner than their controls due to a 
lower lipid content of white and brown adipose tissue (Ward et al., 1994; Da Costa et al., 
1994).  
In H-2Kb-IGF-II transgenic mice, the transgene expression is barely detectable before birth 
but then can be found in thymus, spleen, and low in liver and kidney. Serum levels are ~6 - 8-
fold increased. Transgenic mice display no alterations in body and organ growth except for a 
significant increase in the weight of the thymus (van Buul-Offers et al., 1995; Van der Ven et 
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al., 1997). In BKVI-IGF-II as well as in H-2Kb-IGF-II transgenic mice no incidence for tumor 
formation is found. 
In the last few years, many additional transgenic mouse models overexpressing IGF-II under 
different promoters have been generated (Petrik et al., 1999; Devedjian et al., 2000; 
Moorehead et al., 2001; Moorehead et al., 2003; Zaina et al., 2002; Zaina et al., 2003). 
However, in none of these studies, a positive effect of IGF-II on postnatal growth was 
described. 
In 1994, PEPCK-IGF-II transgenic mice were generated in our lab, as described in chapter 
3.3.2. In heterozygous PEPCK-IGF-II transgenic mice, transgene-specific mRNA is found in 
liver, kidney, and several parts of the gut (duodenum, jejunum, ileum, and colon) from around 
birth onwards. Compared to wildtype controls, these mice show 2-3 fold higher serum IGF-II 
levels, even increasing after starvation. Serum IGF-II levels are significantly higher in male 
than in female mice, whereas no difference can be detected in different ages. Overall, serum 
IGF-I levels are lower in PEPCK-IGF-II transgenic mice than in wildtype siblings but sex 
related differences can be seen in both groups. Interestingly, transgenic males display 
significantly lower IGF-I levels than transgenic females, whereas wildtype males show 
significantly higher IGF-I levels than their female counterparts (Wolf et al., 1994). Serum 
IGF-II levels in these mice are lower than the physiological values in humans and do not have 
metabolic consequences such as hypoglycaemia (Wolf et al., 1994). Also no incidence for 
tumor formation is found. Investigations on body and organ growth in 4- and 12-week-old 
mice revealed that body growth is not significantly influenced by postnatally elevated IGF-II, 
but in transgenic animals the weight of kidneys and testis is increased at the age of 4 weeks, 
as well as the weight of the adrenal glands at an age of 12 weeks (Wolf et al., 1994; Weber et 
al., 1999). Studies of multiple bone parameters in PEPCK-IGF-II transgenic mice showed that 
moderate increased levels of IGF-II do not cause major changes in skeletal growth and 
turnover in mice (Wolf et al., 1995). 
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3  Animals, materials and methods 
 
3.1  Animals 
 
3.1.1  IGF-I knockout mice 
 
The generation of IGF-I deficient mice by homologous recombination in embryonic stem 
(ES) cells has been previously described (Powell-Braxton et al., 1993). Briefly, gene targeting 
was obtained by insertion of a reverse orientated neomycin cassette in exon 3, leading to 
additional multiple stop codons in all IGF-I B chain reading frames. Targeted ES cells 
(129/Sv) were injected into C57BL/6J blastocysts, and the embryos were reimplanted into 
pseudopregnant females (CD1). Heterozygous offspring for the expected mutation was 
derived from parental chimeric mice and identified by Southern blot analysis using tail DNA. 
Mice homozygous for the IGF-I mutation were generated by intercrossing of heterozygotes. 
At birth, homozygous IGF-I knockout mice were 60% of weight of their littermates and until 
adulthood they only reached 30% of normal size. More than 95% of these pups died 
perinatally. Both sexes lacked libido and were infertile. Heterozygous IGF-I knockout mice 
were found to be slightly smaller (~10%) than their wildtype littermates but they were fertile 
and healthy. 
The mice used for our experiment were kindly provided by Dr. Pieter A.F.M. Doevendans, 
University of Maastricht, Netherlands in cooperation with MD Cecilia Camacho-Hübner, 
Departments of Endocrinology and Chemical Endocrinology, St Bartholomew’s Hospital, 
London, United Kingdom. We obtained two female and two male heterozygous IGF-I 
knockout mice on the original background. In our lab they were intercrossed with NMRI mice 
to obtain an outbred background of 50%. 
 
3.1.2  PEPCK-IGF-II transgenic mice 
 
PEPCK-IGF-II transgenic mice harbor fusion genes in which a human IGF-II complementary 
DNA is placed under the transcriptional control of the rat phosphoenolpyruvate carboxykinase 
(PEPCK) promoter. They were generated by pronuclear injection as previously described 
(Wolf et al., 1994). Briefly, a fragment including 550 bp of the PEPCK promoter, 120 bp of 
rat insulin II intron A sequences, the 768 bp human IGF-II cDNA, and 420 bp of the 
terminating sequences of the human GH gene was microinjected into pronuclei of zygotes 
from superovulated B6D2F1 mice (Charles River-WIGA) (Figure 3-1). Injected zygotes were 
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transferred to synchronized recipients (NMRI, Charles River-WIGA). Transgenic founder 
animals were mated to nontransgenic mice to set up transgenic lines. More than six 
generations were necessary to achieve over 98% NMRI background. 
PEPCK-IGF-II transgenic mice were shown to overexpress IGF-II with serum IGF-II levels 
2-3 times higher than those in controls. For the transgenic animals values in a range of ~130-
160 ng/ml and ~30-60 ng/ml for the controls were detected. Transgene-specific messenger 
RNA was detected in liver, kidney and several parts of the gut (Wolf et al., 1994).  
 
 
 
3.1.3  Crossbreeding  
 
Since our aim was to study the role of postnatally elevated IGF-II in the absence of IGF-I we 
wanted to obtain mice lacking IGF-I and overexpressing IGF-II. Therefore the mating was 
done as described below. 
Due to the infertility of IGF-I-deficient mice, two mating steps were necessary (Figure 3-2). 
First, heterozygous IGF-I knockout mice [I+/-] (50 % NMRI background) were mated with 
heterozygous PEPCK-IGF-II transgenic mice [IItg] (~100 % NMRI background), generating 
four different genetic groups: animals lacking one IGF-I allele and wildtype for the PEPCK-
IGF-II transgene [I+/- IIwt], lacking one IGF-I allele and habouring the PEPCK-IGF-II 
transgene [I+/- IItg], wildtype for the IGF-I mutation and carrying the PEPCK-IGF-II 
transgene [I+/+ IItg], and completely wildtype [I+/+ IIwt]. In a second step, [I+/- IIwt] and [I+/- 
IItg] were mated to obtain two additional groups: homozygous IGF-I knockout and PEPCK-
IGF-II wildtype mice [I-/- IIwt] and homozygous IGF-I knockout and PEPCK-IGF-II 
transgenic mice [I-/- IItg]. Thus, the resulting genetic background was nearly ~75% NMRI. 
 
 
 
BstXI 
PEPCK IGF-II int hGH pA 
Spel EcoRI Pstl 
2 kb 
EcoRI 
Figure 3-1: Schematic representation of PEPCK-IGF-II (Wolf et al., 1994). The 
construct includes the 550 bp PEPCK (phosphoenolpyrovate carboxykinase) 
promoter, 120 bp rat insulin II intron A sequences, the 768 bp human IGF-II cDNA 
and 420 bp of the terminating sequences of human GH gene.  
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Step 1:
Step 2:
X
[I+/-] [II tg]
[I+/+ IIwt] [I+/+ IItg] [I+/- IIwt] [I+/- IItg]
[I+/+ IIwt] [I+/+ IItg] [I+/- IIwt] [I+/- IItg]
X
[I+/- IIwt] [I+/- IItg]
[I-/- IIwt] [I-/- IItg]
Mating Scheme
Figure 3-2: Mating scheme. The mating was done in two steps. In step 1, heterozygous IGF-I 
knockout mice [I+/-] were crossed with heterozygous PEPCK-IGF-II transgenic mice [IItg]. From 
the obtained offspring we mated the animals lacking one IGF-I allele and wildtype for PEPCK-IGF-
II transgene [I+/- IIwt] with individuals lacking one IGF-I allele and carrying the PEPCK-IGF-II 
transgene [I+/- IItg]. 
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3.1.4  Animal husbandry 
 
All animals were maintained under specified pathogen-free conditions in a closed barrier 
system (sanitary trap system, sterile clothing, medical gloves, chemical material sluice, 
handing through autoclave, positive pressure ventilation) at 22°C, 65% humidity and a 12 h 
light / 12 h dark cycle.  
Mice were housed separated by sex in open cages (Macrolon type II, type II long and type III) 
on static racks and had free access to a standard rodent diet (V1534 and V1126 for pregnant 
and lactating animals, Ssniff) and HCl-acidified tap water (pH 2.5-3).  
Health monitoring screening programmes were based on the FELASA guidelines for breeding 
colonies and experimental units. Our programmes involved examinations at intervals of three 
months. 
The animals were weaned at an age of four to five weeks, marked by ear piercing and tail tips 
were clipped and frozen on dry ice for genotype analysis. 
 
 
3.2  Mouse genotyping 
 
3.2.1  Proteinase K digests of mouse tail tips 
 
Reagents: 
EDTA     ethylene diamine tetraacetic acid, 0.5 M, pH 8.0 
Proteinase K Solution  20 mg/ml dissolved in bidistilled H2O 
Isopropanol    100% 
Ethanol     70% 
 
Wizard® Genomic DNA Purification Kit (Promega) containing: 
Nuclei Lysis Solution 
RNase Solution 
Protein Precipitation Solution 
DNA Rehydration Solution 
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Assay procedure: 
Tail tips (about 0.5 cm), stored at -80°C, were incubated overnight with gentle shaking in 1.5 
ml centrifuge tubes containing 120 ml EDTA, 500 µl Nuclei Lysis Solution and 17.5 µl 
Proteinase K. On the next morning, 3 µl of RNase Solution were added, the samples were 
mixed by inverting 25 times and incubated for 25 minutes at 37°C. After cooling down to 
room temperature, 200 µl of Protein Precipitation Solution were added to the sample. The 
samples were vortexed at high speed for 20 seconds, chilled on ice for five minutes and then 
centrifuged at 20,800 x g for 4 minutes. The supernatant was transferred into a clean 1.5 ml 
centrifuge tube containing 600 µl isopropanol. The DNA became visible by gentle shaking 
and was pelleted by centrifugation at 20,800 x g for two minutes. After carefully decanting 
the supernatant, 600 µl of 70% ethanol were added to wash the DNA. The samples were 
inverted several times and then centrifuged at 20,800 x g for 2 minutes.  Ethanol was carefully 
removed with a pipette tip and the pellet air-dried for 10-15 minutes.  50 µl of Rehydration 
Solution were added and the DNA was rehydrated by incubating at 65°C for one hour. DNA 
was stored at 2-8°C. 
 
3.2.2  Determination of DNA concentration 
 
For the determination of the DNA concentration, optical density (OD) of samples (each 100 
µl at a dilution of 1:100) was measured against 100 µl bidistilled H2O at a wavelength of 260 
nm as well as 280 nm (Spectrophotometer, Beckmann). Ratios (260/280 nm) between 1.7 and 
2.0 proved a sufficient purity of the samples. The DNA was diluted to a concentration of 100 
ng/µl. 
 
3.2.3  Principle of the Polymerase Chain Reaction (PCR) 
 
PCR is an in vitro method that allows up to a billion fold amplification of a selected DNA 
sequence. The reaction uses two oligonucleotide primers that hybridize two opposite strands 
and flank the target DNA sequence that is to be amplified. In the presence of 
deoxyribonucleoside triphosphates (dNTPs), a heat-stable DNA polymerase catalyzes the 
elongation of the primers. A repetitive series of cycles involving template denaturation, 
primer annealing, and extension of the annealed primers by the polymerase results in 
exponential accumulation of a specific DNA fragment. Because the primer extension products 
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synthesized in a given cycle can serve as a template in the next cycle, the number of target 
DNA copies increases exponentially corresponding to each cycle. 
 
3.2.4  PCR protocol for detecting the IGF-I knockout sequence 
 
The following reagents were used for all PCRs described below: 
 
Reagents: 
 
Taq DNA polymerase Kit (Qiagen) containing: 
PCR Buffer, 10x   TrisCl, KCl, (NH4)2SO4, 15 mM MgCl2, pH 8.7 (20°C) 
Q-Solution   5x concentrated   
MgCl2    25 mM 
Taq Polymerase 5 U/µl, recombinant 94-kDa DNA polymerase, isolated from 
Thermus aquaticus, cloned in E. coli 
 
dNTP Set 100 mM aquaeous solutions of dATP, dCTP, dGTP and dTTP 
each in a separate vial 
 
Ethidium Bromide  0.1% solution in bidistilled H2O 
 
50x TAE running buffer 242 g Tris 
    57.1 ml Glacial Acetic Acid 
    100 ml EDTA, 0.5 M, pH 8.0 
    ad 1 l bidistilled H2O 
 
6x Loading Dye  30% Glycerol 
    Bromophenol Blue 
    
Sequences of the “IGF-I primers” detecting the wild type allele: 
IGF-I s   = 5´- GAC CAG TAG CAA AGG ACT TAC CAC - 3´ 
IGF-I as = 5´- CAC ACC TGG CTC CCC GAA AAT GAA - 3´ 
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Sequences of the “Neo-Primers” detecting the disrupted allele (neomycin cassette): 
Neo s   = 5´- TGA CTG GGC ACA ACA GAC AAT CGG - 3´ 
Neo as   = 5´- GTA GCC AAC GCT ATG TCC TGA TAG  - 3´ 
 
Assay procedure: 
For this PCR two pairs of primers were used, one detecting the wildtype allele (IGF-I sense 
and antisense oligonucleotide), the other detecting the disrupted allele (Neo sense and 
antisense oligonucleotide). For detecting the wildtype allele, primers were derived from 
sequences upstream of exon 3 and downstream of the neomycin insertion in this exon 
resulting in a 366 bp product. For detection of neomycin, primers producing a 608 bp 
fragment were used. To give bands of an equal intensity in the heterozygotes, a ratio of 4:1 
IGF-I/neo primer was used in each reaction (Powel-Braxton et al., 1993).  
The 20 µl reaction was prepared in 100 µl PCR reactions tubes on ice, containing: 
DNA Template    1.00 µl (about 100 ng DNA) 
IGF-I sense primer, 8 µM  1.00 µl 
IGF-I antisense primer, 8 µM 1.00 µl 
Neo sense primer, 2 µM  1.00 µl 
Neo antisense primer, 2 µM  1.00 µl 
dNTP Mix, 1 mM   3.00 µl 
PCR Buffer, 10x    2.00 µl 
Q-Solution    4.00 µl  
MgCl2, 25 mM   1.25 µl 
Taq Polymerase, 5U/µl  0.10 µl 
Bidistilled H2O   4.65 µl 
 
DNA of a hetero- and homozygous IGF-I knockout and of a wildtype mouse was used as a 
positive control and a non-template negative control (H2O) to check for contamination. 
The amplification took place in a Biometra Uno Cycler and was performed as follows: 
1st step: denaturation 94°C for 4 minutes 
2nd step: denaturation 94°C for 1 minute 
3rd step: annealing 66°C for 1 minute 
4th step: extension 72°C for 2 minutes 
5th step: extension 72°C for 10 minutes 
6th step: cooling at          4°C 
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Steps 2 to 4 were repeated 36 times before progression to the final extension step 5 and 
cooling down. Amplified products were electrophoretically separated on 2% TAE agarose 
gels. For this purpose 1 g agarose was mixed in 50 ml 1x TAE buffer and boiled. 4 µl 
ethidium bromide were added and the mixture was filled into a running chamber. After 
approximately half an hour the gel solidified and the chamber was filled up with 1x TAE 
running buffer. PCR products and a DNA standard (pUC Mix Marker, MBI) were mixed with 
4 µl loading dye and were pipetted into the slots. The run was started at 90 V for 45 minutes. 
Amplified products were visualized under UV-light (Eagle Eye II, Strategene). Wild type 
animals showed a band at a size of 366 bp, homozygous IGF-I knockout mice at a size of 608 
bp. Heterozygous IGF-I knockout mice showed both bands (Figure 3-3).  
 
 
 
3.2.5  PCR protocol for detecting the PEPCK-IGF-II transgene 
 
Sequence of the human IGF-II PCR sense primer:  
hIGF-II #5 = 5’ - ATG GGA ATC CCA ATG GGG AAG - 3’ 
 
Sequence of the human IGF-II PCR antisense primer:   
hIGF-II #10 = 5’ - CGG GGT CTT GGG TGG GTA GAG - 3’ 
 
Assay procedure: 
For this PCR primers specific for the PEPCK-IGF-II construct were used. The 20 µl reaction 
was prepared in 100 µl PCR reaction tubes on ice, containing: 
 
 
883 
 
692 
 
 
501 
489 
 
 
404 
331 
 
 M       +/+        +/+         +/-        +/-        -/-         -/-     H20 
Figure 3-3: Detection of the IGF-I mutant allele. Homozygous IGF-I 
knockout animals (-/-) show a fragment at the size of 608 bp, wildtype animals 
(+/+) at the size of 366 bp. Heterozygous IGF-I knockout animals (+/-) show 
both fragments. 
 bp 
Animals, materials and methods 
__________________________________________________________________________________________ 
34
DNA template    1.00 µl (about 100 ng DNA) 
hIGF-II #5 primer, 2 µM  1.00 µl 
hIGF-II #10 primer, 2 µM  1.00 µl 
dNTP Mix, 1 mM   2.00 µl 
PCR Buffer, 10x    2.00 µl 
Q-Solution    4.00 µl  
MgCl2, 25 mM   1.25 µl 
Taq Polymerase, 5 U/µl  0.10 µl 
Bidistilled H2O   7.70 µl 
 
DNA of a heterozygous PEPCK-IGF-II transgenic mouse was used as a positive control and a 
non-template control to check for contamination. 
The amplification took place in a Biometra UnoII Cycler and was performed as follows: 
1st step: denaturation 94°C for 4 minutes 
2nd step: denaturation 94°C for 1 minute 
3rd step: annealing 63°C for 1 minute 
4th step: extension 72°C for 2 minutes 
5th step: extension 72°C for 10 minutes 
6th step: cooling at          4°C 
Steps 2 to 4 were repeated 35 times before progression to the final extension step 5 and 
cooling down. Amplified products were electrophoretically separated on 2% TAE agarose 
gels as described before. Amplified products were visualized under UV-light. PEPCK-IGF-II 
transgenic mice showed a band at a size of 498 bp (Figure 3-4). 
 
 
 
 
 
 M          wt        tg         wt        wt         tg         wt      H20   bp 
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Figure 3-4: Detection of the PEPCK-IGF-II sequence. Transgenic animals 
show a fragment at a size of 498 bp. 
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3.3 Evaluation of  gene expression at RNA levels 
 
To determine the beginning of the transgenic IGF-II expression we investigated the RNA 
levels in liver and kidneys of embryos at day 17.5 and 19.5 p.c. as well as of pups at day four 
after birth.  
We mated heterozygous PEPCK-IGF-II transgenic mice with NMRI. To obtain the embryonic 
stages day 17.7 and 19.5 pregnant mice were killed by cervical dislocation and the embryos 
were prepared from the uterus. Embryos and pups were killed by decapitation. Liver, kidneys 
as well as a piece of tail for genotyping were dissected and frozen on dry ice. The organ 
samples were stored at -80°C until further investigation. Genotyping was done as described in 
3.2.5. 
 
To avoid degradation by nucleases, following rules were observed with the extraction, 
manipulation or analysis of RNA: 
• Disposable gloves were worn all the time and changed frequently 
• All equipment was autoclaved, glasses and magnetic stirrers sterilized at 180°C for 8 h 
• All solutions, except those containing Tris, were made with DEPC-H2O (0.1 % 
diethylpyrocarbonate) 
 
3.3.1 RNA extraction 
 
Reagents: 
TRIzol® Reagent, mono-phasic solution of phenol and guanidine 
Invitrogen, Germany isothiocyanate 
Chloroform    100% 
Isopropanol    100% 
Ethanol    75%, in DEPC-treated water 
Bidistilled H2O   RNase-free 
 
Assay procedure: 
Tissue samples (50-100 mg) stored at -80°C were added directly into 2 ml safe-lock tubes 
(Eppendorf) containing 1 ml of the TRIzol® Reagent and homogenized with a tissue 
homogenizer at 23500 rpm (ART Labortechnik). After each sample, the homogenizer was 
cleaned with bidistilled water and 0.2 M NaOH and shortly run in TRIzol® Reagent to avoid 
dilution of the samples. Homogenized samples were incubated for 5 minutes at room 
Animals, materials and methods 
__________________________________________________________________________________________ 
36
temperature to permit the complete dissociation of nucleoprotein complexes. 0.2 ml 
chloroform were added. After vortexing the tubes vigorously for 15 seconds the samples were 
incubated at room temperature for 2 to 3 minutes and centrifuged at 12,000 x g for 15 minutes 
at 2 to 8°C. Following centrifugation, the mixture separated into a lower red, phenol-
chlorofrom phase, an interphase, and a colourless upper aquaeous phase. RNA remained 
exclusively in the aquaeous phase. 
The aqueous phase was transferred into a fresh tube containing 0.5 ml isopropanol. Samples 
were mixed, incubated at room temperature for 10 minutes, and centrifuged at 12,000 x g for 
10 minutes at 4°C, respectively. After removing the supernatant, 1 ml of 75% ethanol was 
added; the samples were mixed by vortexing and centrifuged at 7,500 x g for 5 minutes at 
4°C. Afterwards, the ethanol was carefully removed with a pipette tip and the RNA pellet was 
air-dried for 5 to 10 minutes. Finally, the pellet was dissolved in RNase-free water. 
RNA concentration was estimated in the same way as DNA concentration and calculated with 
the following formula: 
RNA concentration (µg/ml): dilution factor x OD260 x 40 (unit factor) 
 
3.3.2 Reverse Transcription PCR (RT-PCR) 
 
Reagents : 
10 x Reaction Buffer    Tris 10 mM, MgCl2 10 mM, pH 7.4, DEPC 
treated 
DNase I     diluted 1:10 with bidistilled H2O 
Random Hexamer Primers   3 µg/µl in 3 mM Tris-HCl (pH 7.0), 0.2 mM 
EDTA 
dNTPs      10 mM 
5 x Reaction Buffer    M-MLV Reverse Transcriptase Buffer 
DTT      10 mM (Dithiothriteol) 
Reverse Transcriptase   200 U/µl (M-MLV Reverse Transcriptase) 
 
Assay procedure: 
A DNase I digest was performed with 5 µg of total RNA. The reaction mix was prepared on 
ice and contained the following: 
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RNA, 5 µg    16 µl 
10 x Reaction Buffer     2 µl  
DNase I      2 µl 
The samples were incubated at 37°C for 30 minutes. Thereafter, the enzyme was inactivated 
by incubation at 75°C for 10 minutes. 
 
10 µl of the DNase I digest (= 2.5 µg RNA) were used for reverse transcription. The reaction 
mix was prepared on ice and contained the following: 
DNase digested RNA   10.0 µl 
DTT       2.0 µl  
Random Hexamer Primers    1.0 µl 
dNTPs       2.0 µl 
Reverse Transcriptase    0.1 µl 
Bidistilled H2O     0.9 µl 
For reverse transcription samples were incubated at 37°C for 30 minutes. The enzyme was 
inactivated by incubation at 95°C for 10 minutes.  
 
3.3.3 β-Actin PCR 
 
Sequence of the β-Actin sense primer:  
β-Actin #1 = 5’ - GGC ATC GTG ATG GAC TCC - 3’ 
 
Sequence of the β-Actin antisense primer:  
β-Actin #2 = 5’ - CTC GGA AGG TGG ACA GGG - 3’ 
 
Assay procedure: 
To confirm the correct reverse transcription from RNA into cDNA, a sequence of the house-
keeping gene β-Actin was amplified. The 20 µl reaction was prepared in 100 µl PCR reactions 
tubes on ice, containing: 
DNase digested RNA or 
cDNA     1.00 µl 
β-Actin #1 primer, 2 µM  1.00 µl 
β -Actin #2 primer, 2 µM  1.00 µl 
dNTP Mix, 1 mM   2.00 µl 
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PCR Buffer, 10x    2.00 µl 
Q-Solution    4.00 µl  
MgCl2, 25 mM   1.25 µl 
Taq Polymerase, 5 U/µl  0.10 µl 
Bidistilled H2O   7.70 µl 
Genomic DNA of a heterozygous PEPCK-IGF-II transgenic mouse was used as a positive 
control and a non-template control to check for contamination. 
The amplification took place in a Biometra UnoII Cycler and was performed as follows: 
1st step: denaturation 94°C for 4 minutes 
2nd step: denaturation 94°C for 1 minute 
3rd step: annealing 60°C for 1 minute 
4th step: extension 72°C for 2 minutes 
5th step: extension 72°C for 10 minutes 
6th step: cooling at          4°C 
Steps 2 to 4 were repeated 35 times before progression to the final extension step 5 and 
cooling down. Amplified products were electrophoretically separated on 2% TAE agarose 
gels as described before. Amplified products were visualized under UV-light. DNA 
contamination in the RNA preparations could be excluded since no bands were detected when 
RT-probes were loaded on a 2% agarose gel. 
 
3.3.4 PEPCK-IGF-II PCR 
 
The PEPCK-IGF-II PCR was performed as previously described (see chapter 3.2.5), using 3 
µl of cDNA as a template.  
 
 
3.4 Evaluation of gene expression at the protein level 
 
3.4.1 Blood and serum collection 
 
Blood samples from adult mice were obtained via bleeding from the retro-orbital sinus under 
ether anaesthesia. Embryos and pups were killed by decapitation and the blood was collected 
with a capillary tube from the cut. 
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Blood serum was collected from coagulated samples by centrifugation at 20,800 x g for 10 
minutes at room temperature. The supernatant was transferred into a new plastic tube and 
stored at -20°C until further investigation. 
 
3.4.2 Western ligand and immunoblot analysis 
 
3.4.2.1 SDS-PAGE 
 
Reagents: 
Separating Gel (12%)  1.675 ml bidistilled H2O 
    1.25 ml Tris, pH 8.8, 1.5 M 
    2 ml Acryl Amide, 30% 
    50 µl SDS (Sodium Dodecyl Sulfate), 10% 
    2.5 µl TEMED (N, N ,N’; N’-Tetrametylethylendiamine) 
    25 µl APS (Ammonium Persulfate), 10% 
 
Stacking Gel (5%)  1.75 ml bidistilled H2O 
    0.3125 ml Tris, pH 6.8, 0.5 M 
    0.375 ml Acryl Amide, 30% 
    1.25 µl TEMED (N, N ,N’; N’-Tetrametylethylendiamine) 
    25µl APS (Ammonium Persulfate), 10% 
 
Laemmli Buffer (2x)  12.5 ml Tris/HCl, 1 M, pH 6.8 
    4 g SDS (Sodium Dodecyl Sulfate) 
    20 ml Glycerine 
    2 ml Bromophenol Blue, 1% 
    ad 100 ml bidistilled H2O 
 
Running Buffer (10x)  30.3 g/l Tris, 48 mM 
    144 g /l Glycine 
    10 g /l SDS 
    ad 1 l bidistilled H2O 
 
2-mercaptoethanol  100% 
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Assay procedure: 
The serum proteins were separated using the Mini Protean II™ System. The separating gel 
(12% acrylamide) was prepared in an Erlenmeyer Flask under continuous agitation and 
poured into the gap between the glass plates of the system, leaving enough space for the 
stacking gel (about 2,5 cm). To ensure an even surface the stacking gel was overlaid with 
bidistilled water and kept for one hour at room temperature for polymerisation. After 
complete polymerisation, the water was discarded and the stacking gel (5% acrylamide, 
prepared in the same way as the separating gel) was loaded on top.  The comb was inserted 
taking care not to trap air bubbles under the teeth. While keeping the gel for 30 minutes at 
room temperature for polymerisation the samples were prepared as follows: 1 µl serum, 9 µl 
bidistilled H2O, 10 µl 2x Laemmli buffer and (only for  Western immunoblot) 1 µl 2-
mercaptoethanol were mixed, incubated at 95°C for 5 minutes, chilled on ice for one minute 
and kept at room temperature afterwards.  
After complete polymerisation of the stacking gel, the comb was removed and the plates were 
mounted in the electrophoresis apparatus being filled up with running buffer. Samples and a 
standard marker (Protein Molecular Weight Marker, #SM0431, MBI) were loaded. Electro-
phoresis was performed initially at 100 V for 10 minutes and then at 160 V for approximately 
60 minutes until the bromophenol blue left the separating gel at the bottom. 
  
3.4.2.2 Electroblotting 
 
Reagents: 
Transfer Buffer (10x)  58 g Tris/l  
    29 g/l Glycin 
    3.7 g/l SDS 
    ad 1 l  bidistilled H2O 
 
Transfer Buffer  5 ml 10x Transfer Buffer 
(for 1 gel)   32 ml bidistilled H2O  
    10 ml Methanol, 100% 
   
Ponceau Red   2 g Ponceau S 
    30 ml Acetic Acid 
    ad 1 l bidistilled H2O  
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Assay procedure: 
Separated proteins were transferred to a nitrocellulose membrane by semidry electrophoretic 
blotting in the MilliBlot-Graphite Electroblotter (Millipore). The nitrocellulose membrane 
was incubated in 100% methanol for 10 minutes and in the complete transfer buffer for 30 
minutes. Six sheets of Whatman paper cut to the same size as the gel were soaked in transfer 
buffer, stacked on top of each other on the bottom electrode and squeezed with a glas tube to 
remove the air bubbles. The nitrocellulose membrane and then the gel were placed exactly on 
the paper stack and were covered with another stack of six soaked Whatman paper sheets. The 
upper electrode was placed and the system was connected to a power supply. The transfer 
took place for 90 minutes at 60 mA for each gel (1A/cm2). 
 
After the transfer, the membrane was labeled with a pen and the molecular weight standard 
bands were marked. The membrane was stained with Ponceau red, dried and stored at 4°C. 
 
3.4.2.3 Western Ligand Blot 
 
Reagents: 
Tris-buffered Saline  1.21 g Tris 
(TBS)    8.76 g NaCl 
    ad 1 l bidistilled H2O 
    HCl ad pH 7.4 
 
Tris-buffered Saline + 485 ml Tris-buffered Saline, pH 7.4 
3% NP-40   15 ml Nonidet P-40,  
 
Tris-buffered Saline + 500 ml Tris-buffered Saline, pH 7.4 
0.1% Tween 20  500 µl Tween®-20,  
 
Tris-buffered Saline + 5 ml Tris-buffered Saline, pH 7.4 
1% fish-gelatin  50 µl Fish Gelatin  
 
Tracer    5 ml Tris-buffered Saline, pH 7.4 
    50 µl Fish Gelatin 
    500,000 cpm/ml [125I]-IGF-II Tracer 
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Assay procedure:   
The major advantage of this method compared to traditional Western immunoblotting is the 
possibility of detecting bioactive IGFBPs. Ligand blot analysis of serum IGFBPs was 
performed using [125I]-IGF-II as a tracer according to the method of Hossenlopp at al. (1986). 
The membrane containing the separated proteins was washed and hybridized in 50 ml conical 
tubes in a hybridization oven at 4°C according to the following scheme: 
• Washing in Tris-buffered Saline + 3% NP-40 for 20 minutes 
• Blocking in Tris-buffered Saline + 1% Fish Gelatin for 120 minutes 
• Washing in Tris-buffered Saline + 0.1% Tween®-20 for 20 minutes 
• Incubation with tracer overnight 
The next day, blots were washed again according to the following scheme: 
• 2x washing in Tris-buffered Saline + 0.1% Tween®-20 for 30 minutes  
• 3x washing in Tris-buffered Saline for 30 minutes 
The membrane was dried and IGFBPs were visualized on Storage Phosphor Image and X-ray 
films. 
 
3.4.2.4 Western Immuno Blot 
 
Reagents: 
TBS-T    500 µl Tween®-20 
    ad 1 l TBS 
 
Blocking Solution  2.5 g instant skimmed milk (spray dried) 
    ad 1 l TBS-T 
 
Primary Antibody anti-mGH antibody from rabbit, diluted 1:20,000 in blocking 
solution (Dr. A.F. Parlow, National Hormone & Piatury 
Programme, USA) 
 
Secondary Antibody anti-rabbit antibody from goat, diluted 1:4000 in blocking 
solution (Cell Signaling Technology) 
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Assay procedure: 
The membrane containing the separated proteins was dried at 37°C for 30 minutes and then 
incubated with blocking solution in a hybridization oven at room temperature for 60 minutes. 
After blocking, incubation with the primary antibody took place at room temperature for 60 
minutes. The membrane was washed 3 times for 5 minutes at room temperature with TBS-T. 
Incubation with the secondary antibody occurred for 60 minutes at room temperature. The 
membrane was washed 3 times with TBS-T and finally once in TBS for 10 minutes at room 
temperature. Detection was performed by incubating the membrane with 2 ml of the Western 
blotting luminol detection reagent (Santa Cruz). The membrane was sealed under plastic and 
exposed to an ECL Hyper film. 
 
3.4.3 Radioimmunoassay (RIA) 
 
Specific radioimmunoassays of the blood serum for IGF-I, IGF-II and IGFBP-2 were kindly 
performed by Karin Weber (laboratory of Dr. Martin Elmlinger, University Childrens 
Hospital, Tuebingen, Germany) as previously described (Blum et al., 1988; Blum et al., 1992; 
Ranke et al., 2003). For all assays, dilution curves of mouse serum samples were linear, and 
paralleled those of human standards. 
 
 
3.5 Analysis of body and organ growth 
 
Body weight of selected litters (identified by palm-tattooing) was recorded daily, starting 
from day three or four after birth until day 45. From this date on, mice were weighed twice a 
week until day 60. At day 60 mice were killed by bleeding from the retro-orbital sinus under 
ether anaesthesia and the nose-rump-length was determined. The nose-rump-length was 
measured as the distance between nose and base of the tail. At necropsy, thymus, heart, lung, 
spleen, liver, kidneys, adrenal glands, pancreas, abdominal fat, testes and ovaries were 
dissected, blotted dry on tissue paper and weighed to the nearest mg. For bilateral organs, the 
paired weight was recorded. Carcasses were weighed to the nearest 0.1 g after removal of the 
organs, skin, head and tail.  
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3.6. Bone parameters 
 
3.6.1 Bone preparation 
 
Reagents: 
Calcein Solution   10 ml NaCl 
     140 mg NaHCO3 
     40 mg Calcein 
 
Phosphate-buffered Saline (PBS) 8 g NaCl, 137 mM 
0.2 g KCl, 2.7 mM  
1.44 g Na2HPO4, 10 mM 
0.24 g KH2PO4, 2 mM 
ad 1 l bidistilled H2O  
HCl ad pH 7.4      
 
Paraformaldehyde, 4%  40 g Paraformaldeyde  
     PBS ad 1 l 
     250 µl NaOH, 5 M 
     HCl, 37% ad pH 7.2-7.4 
 
Assay procedure: 
The injection of calcein was performed subcutaneously 72 and 24 hours before necropsy. 
Doses were calculated as follows: injection volume in µl = 5x body weight (g). The calcein 
application was done in accordance to the German law on Animal Protection and approved by 
the Bavarian Animal Research Authority (Az. 209.1/211-2531.2-29/03). 
Both femurs and the lumbar vertebraes were isolated from the carcass and carefully defleshed. 
The right femur and the first lumbar vertebrae were fixed in 4% paraformaldehyde for 24 
hours at 4°C, the left femur and the remaining lumbar vertebraes were conserved in 70% 
ethanol. 
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3.6.2 Bone histology 
 
Bone histology and bone mineral density measurements, briefly described below, were kindly 
performed by the lab of PD Dr. Reinhold Erben, Institute of Animal Physiology, Veterinary 
Faculty, LMU Munich. 
After washing overnight in 10% sucrose/PBS-solution at 4˚C, the fixed right femurs and first 
lumbar vertebraes were subsequently dehydrated and embedded undecalcified in methyl-
methacrylate as previously described (Erben, 1997). Three-µm-thick sections were prepared 
using a HM 360 microtome (Microm, Walldorf, Germany), and stained with von 
Kossa/McNeal (Schenk et al., 1984). 
 
3.6.3 Bone mineral density measurements 
 
Bone mineral density (BMD) of the left femur was measured by peripheral quantitative 
computed tomography (pQCT) using a XCT Research M+ pQCT machine (Stratec 
Medizintechnik, Pforzheim, Germany). One slice (0.2-mm-thick) in the mid-diaphysis of the 
femur, and 3 slices in the distal femoral metaphysis located 1.5, 2.0, and 2.5 mm proximal to 
the articular surface of the knee joint were measured. BMD values of the distal femoral 
metaphysis were calculated as the mean over 3 slices. A voxel size of 0.070 mm and a 
threshold of 600 mg/cm³ were used for calculation of cortical BMD. 
 
3.7  Statistical analysis 
 
The average growth of individual groups was estimated by transforming body weight data to a 
weighing day of n x 3 by linear interpolation as described previously (Wolf et al., 1991). 
Body weight and organ weight data as well as blood serum parameters were analyzed by the 
General Linear Models procedure (SAS Institute, Inc., Cary, NC), taking the effect of IGF-I 
status (+/+, +/-, -/-), IGF-II status (tg, wt) and sex into account. Means were compared by using 
LSD post hoc tests (SPSS, Inc. [Chicago, IL] program package). 
Bone parameters were analyzed by 3-way ANOVA. The statistical model included IGF-I 
status, IGF-II status, sex, and the various interactions between these factors. 
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3.8 Reagents and Materials 
 
Amersham Pharmacia GmbH  Fish Gelatin (# RPN1636) 
Freiburg, Germany    Hyperfilm™ MP (# RPNK6K) 
      ECL X-ray film (# RPN2103K) 
      Electrophoresis Power supply EPS500/400 
 
AppliChem     Ethylenediaminetetraaceticacid, (EDTA) 
Darmstadt, Germany   (# A3353.1000) 
 
ART Labortechnik    Tissue Homogenizer 
Mühlheim, Germany 
 
Bachhofer     Hybridisation Oven 
Reutlingen, Germany 
 
Beckman Coulter    Spectrophotometer DV 640 
Palo Alto, CA, USA 
 
Becton Dickinson    Falcon® BLUEMax™ conical tube 50 ml 
Franklin Lakes, USA   (# 352070) 
      Falcon® BLUEMax™ conical tube 15 ml 
      (# 352096) 
 
Biometra     Thermocycler UNO thermoblock 
Göttingen, Germany   Thermocycler UNO II thermoblock 
 
BioRad     Acrylamide/Bis Solution, 30% (# 161-0156) 
München, Germany    Ammonium Persulfate, (APS) (# 161-0700) 
Mini Protean II™ system 
      Power Supply POWER PAC 300 
      TEMED (# 161-0800) 
 
Brand      Micro haematocrit Tubes (# 749311) 
Melsungen, Germany 
 
Carl Roth GmbH    Acetic Acid Glacial (# 3738.1)  
Karlsruhe, Germany   DEPC (Diethylpyrocarbonate) (# K028.2) 
Diethyl Ether (# 8.222.70.5) 
Ethanol (# 9065.3) 
      Glycerol (# 3783.1) 
      Glycine (# 3908.2) 
      Methanol (# 46271) 
      Tris (# 4855.2)  
 
Cell Signalling Technology   Anti-Rabbit Antibody (goat) 
 
 
Eppendorf     Centrifuge 5417R  
Hamburg, Germany    Mini Spin Plus 
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      Safe-lock Tubes, 1.5 ml (# 0030 121.848) 
      Safe-lock Tubes, 2.0 ml (# 0030 120.084) 
      Thermomixer 5436 
 
G. Kisker GbR    PCR-Tube-Strips, 0.2 ml (# G002-A) 
Steinfurt, Germany    PCR-Caps-Strips, 0.2 ml (# G004-A) 
 
IKA-Works, Inc.    MS1 Minishaker (# 004124) 
Wilmington, USA 
 
Invitrogen GmbH    M-MLV Reverse Transcriptase (# 28025-013) 
Karlsruhe, Germany  M-MLV Reverse Transcriptase Buffer (# 18057-
018) 
Random Hexamer Primers (# 48190-011) 
Ultra Pure™ Dithiothriteol, (DTT) (# 15508-013) 
      Ultra Pure™ Agarose (# 15510-027) 
     
Fermentas, MBI    dNTP-Set (# R0181) 
St. Leon-Rot, Germany   Prestained Protein Ladder (# SM0671) 
      Protein Molecular Weight Marker (# SM0431) 
      pUC Mix Marker 8 (# SM0301) 
      6x Loading Dye (#R0611) 
 
Fluka      Isopropanol (# 33539) 
Deisenhofen, Germany   Nonidet® P40 (# 74385) 
 
Heirler     Instant Skimmed Milk (spray dried) 
Radolfzell, Germany 
 
Hormone and Pituitary Program,   Mouse Growth Hormone Antigen 
(Dr. A.F. Parlow), USA   Rat Growth Hormone Antiserum (Rabbit) 
 
Invitrogen     TRIzol® (# 15596-018) 
Germany 
       
Merck      Bromophenol Blue Sodium Salt (# 1.11746.0005) 
Darmstadt, Germany   Chloroform (# 1.02445.1000) 
      di-Sodium Hydrogen Phosphate Anhydrous  
(# 1.06586.2500) 
      Dodecyl Sulfate Sodium Salt (# 1.13760.1000) 
      Ethidium Bromide 1% (# 1.11608.0030) 
      Hydrochloric Acid, 37% (# 1.13386.2500) 
      Potassium Chloride, (KCl) (# 1.04936.1000) 
      Potassium Dihydrogen Phosphate (# 1.04873. 
1000) 
      Sodium Chloride (# 1.06404.1000) 
 
Millipore     Immobilon-P PVDF membrane, 0.45 µm  
Bedford, MA, USA   MiliBlot Graphite Electroblotter (# MBB 
DGE001) 
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Molecular Dynamics   Storage Phosphor Screen 
 
MWG-Biotech    Gel chambers 
Ebersberg, Germany   Power Supply PPS 200-1D 
  
Pharmacia     Electrophoresis Power Supply EPS 500/400 
Uppsala, Schweden 
 
Promega     Wizard® Genomic DNA Purification Kit (# 
A1125) 
Madison, USA 
 
Qiagen     Taq DNA Polymerase Kit (# 201205) 
Hilden, Germany     
 
Roche      DNaseI (# 776751) 
Mannheim, Germany   Proteinase K (# 1092766) 
      Random Hexamer Primers (# 1034731) 
Reverse Transcriptase AMV (# 1495062) 
 
Santa Cruz Biotechnology, Inc.  Western Blotting Luminol Reagent (# sc-2048) 
Santa Cruz, California, USA 
 
Schleicher & Schuell   Gel Blotting Paper (# GB002) 
Dassel, Germany 
 
Schubert     Protec Compact 45 (Film Processing machine) 
Munich, Germany 
 
Sigma      2- Mercaptoethanol (# M-3148) 
Taufkirchen, Germany   Paraformaldehyde (# P-6148) 
      Ponceau S solution (# P-7170) 
      Tween® 20 (# P-7949) 
 
Stratagene     Eagle Eye II 
Heidelberg, Germany 
 
USV ELGA     Purelab™ Plus (# PL5121) 
Ransbach Baumbach, Germany 
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4 Results 
 
4.1 Generation of double-mutant mice 
 
Double mutant mice suitable for our experimental purposes were generated by a mating 
scheme in two steps (as described in chapter 3.1.3). In the first step heterozygous IGF-I 
knockout mice [I+/-] were mated with heterozygous PEPCK-IGF-II transgenic mice [IItg]. 
The obtained F1 generation included four different genetic groups on a ~75 % NMRI 
background: animals lacking one IGF-I allele and wildtype for the PEPCK-IGF-II transgene 
[I+/- IIwt], lacking one IGF-I allele and harbouring the PEPCK-IGF-II transgene [I+/- IItg], 
wildtype for the IGF-I mutation and carrying the PEPCK-IGF-II transgene [I+/+ IItg], and 
completely wildtype [I+/+ IIwt]. Subsequently, a mating with the following genotypes was 
performed: [I+/- IIwt] x [I+/- IItg]. The resulting offspring comprised animals with six 
different genotypes. In addition to the four genotypes already described ([I+/+ IIwt], [I+/+ IItg], 
[I+/- IIwt], and [I+/- IItg]), we obtained homozygous IGF-I knockout and PEPCK-IGF-II 
wildtype mice [I-/- IIwt] and homozygous IGF-I knockout and PEPCK-IGF-II transgenic 
mice [I-/- IItg].  
All mice were genotyped by established PCR protocols detecting the IGF-I sequence or the 
PEPCK-IGF-II transgene as described in chapter 3.2.4 and 3.2.5. In total, we obtained 397 
animals of 51 litters. Table 4-1 shows the genotype distribution of the obtained animals 
compared to the expected distribution according to the Mendelian inheritance principles.  
 
 
Table 4-1: Expected versus observed distribution of the six different genotypes. In total 397 animals of 51 litters 
have been evaluated. 
 
Distribution Total Genotype 
  [I+/+ IIwt] [I+/+ IItg] [I+/- IIwt] [I+/- IItg] [I-/- IIwt] [I-/- IItg] 
Expected 100% 12.5% 12.5% 25% 25% 12.5% 12.5% 
Observed 
 
100% 
(397) 
13.1% 
(52) 
18.9% 
(75) 
31.5% 
(125) 
22.4% 
(89) 
5.3% 
(21) 
6.8% 
(27) 
 
 
The observed value for [I-/- IIwt] mice was 42.4 % and for [I-/- IItg] mice 54.4 % of the 
expected distribution, indicating a prenatal mortality rate of ~50%. 
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4.2       Expression analysis 
 
4.2.1    Measurement of circulating levels of IGF-I and IGF-II 
 
Radioimmunoassays were performed to measure the plasma levels of IGF-I and-II at day ~60 
postnatal (Table 4-2). IGF-I was not detectable in [I-/- IIwt] and [I-/- IItg] mice. Reduced 
IGF-I levels were present in animals heterozygous for the IGF-I deleted allele ([I+/- IIwt], [I+/- 
IItg]), and the highest values were found in mice harbouring two intact IGF-I alleles ([I+/+ 
IIwt], [I+/+ IItg]). The presence of the IGF-II transgene resulted in reduced levels of IGF-I in 
the groups [I+/- IItg] and [I+/+ IItg]. A statistically significant increase in IGF-II expression 
could be seen in all animals harbouring the PEPCK IGF-II transgene ([I-/- IItg], [I+/- IItg], 
and [I+/+ IItg]) when compared to their IGF-II wildtype counterparts ([I-/- IIwt], [I+/- IIwt], 
and [I+/+ IIwt]). Thus, radioimmunoassays for serum levels of IGF-I and IGF-II demonstrated 
the expected expression of the two peptides reflecting the genotype. 
 
 
Table 4-2: Serum levels (ng/ml) of IGF-I and IGF-II measured by RIA in 60-days-old mice. Data for males and 
females were combined and samples of 80 animals were investigated. Analysis of variance was used to evaluate 
statistically significant differences (∆) between indicated groups (*: P<0.05; **: P<0.01; ***: P<0.001).  
 
 
 genotype ∆ genotype ∆ genotype ∆ 
 [I-/- IIwt] [I-/- IItg]  [I+/- IIwt] [I+/- IItg]  [I+/+ IIwt] [I+/+ IItg]  
IGF-I b b - 351.0 ± 18.3 271.4 ± 19.5 ** 457.1 ± 17.7 375.9 ± 20.2 * 
IGF-II 26.8 ± 8.5 209.2 ± 8.2 *** 56.7 ± 10.7 146.2 ± 11.4 *** 59.9 ± 10.3 123.6 ± 11.8 *** 
n 18 20  11 10  12 9  
    
   b: below detection level. n: number of investigated animals. 
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4.2.2    RT-PCR 
 
To determine the onset of transgenic IGF-II expression, total RNA from liver (Figure 4-1) and 
kidneys (Figure 4-2) (both major sites of endogenous PEPCK expression) of embryos at day 
17.5 and 19.5 as well as of pups at day 4 after birth was extracted. RT-PCR was performed 
using genomic DNA of a PEPCK-IGF-II transgenic animal as a positive control. In both 
figures the first picture displays the PEPCK-IGF-II PCR using the transcribed cDNA as a 
template. The second picture shows a control PCR of the cDNA using the house-keeping gene 
β-Actin in order to confirm the correct reverse transcription and to compare the amounts of 
obtained cDNA. The third picture displays the control PCR for the DNase-I-digest of the 
RNA sample, confirming the absence of genomic DNA. As shown in figure 4-1, transgene 
expression of PEPCK-IGF-II in the liver could be detected from embryonic stage 19.5 
onwards on. On day 4 after birth the obtained signal was visibly stronger. 
 
 
 
 
Contrasting to the findings in the liver, PEPCK-IGF-II transgene expression could not be 
detected in the kidneys in any of the investigated stages (Figure 4-2). 
 
 
Figure 4-1: Expression analysis of the PEPCK-IGF-II transgene in the liver in different 
developmental stages by RT-PCR. M, marker. C, positive control (genomic DNA). H20, 
negative control. nn, neonates. pn, postnatal. 
 M       tg tg  wt wt        tg tg  wt wt      tg tg  wt wt        C H2O  
17.5 e 19.5 e / nn 4 pn 
PEPCK-IGF-II 
cDNA 
β-Actin 
cDNA 
β-Actin        
minus-RT control 
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4.3       Body weight gain 
 
To detect a possible effect on body weight gain of postnatally elevated levels of circulating 
IGF-II in the absence of IGF-I, selected litters were weighed daily from day 3 to 4 after birth 
until day 45. From this date on, body weight was recorded twice a week until day 60. The 
average growth of individual groups was estimated by combining data from males and 
females and transforming it to a weighing day of n x 3 by linear interpolation (as described in 
chapter 3.6).  
In total, the data of 100 animals was analyzed distributed to the genotypes as follows:           
10 [I+/+ IIwt], 21 [I+/+ IItg], 20 [I+/- IIwt], 18 [I+/- IItg], 14 [I-/- IIwt] and 17 [I-/- IItg]. 
 
Regardless of the presence of the PEPCK-IGF-II transgene, the homozygous IGF-I knockout 
animals displayed a body weight at day 3-4 after birth of ~50% as compared to their [I+/+] 
littermates. Figure 4-3 shows a six-day-old litter. Compared to their littermates, homozygous 
IGF-I deficient pups are not only significantly smaller but also display some developmental 
delay (e.g. a postponed emerging of the hair fibres through the epidermis and opening of the 
eyes). 
 
M      tg  tg  wt wt       tg  tg  wt wt     tg  tg  wt wt       C  H2O 
17.5 e 19.5 e / nn 4 p.n. 
β-Actin 
cDNA 
PEPCK-IGF-II 
cDNA 
β-Actin          
minus-RT control 
Figure 4-2: Expression analysis of the PEPCK-IGF-II transgene in the kidney in 
different developmental stages by RT-PCR. M, marker. C, positive control (genomic 
DNA). H20, negative control. nn, neonates. pn, postnatal. 
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The postnatal growth curves in figure 4-4 indicated that in comparison with wildtype 
littermates [I-/- IIwt] and [I-/- IItg] mice continued to grow at a retarded rate after birth and 
reached ~38% of normal weight. The growth curves of [I-/- IIwt] and [I-/- IItg] mice are 
nearly identical, demonstrating that in the absence of IGF-I, elevated levels of circulating 
IGF-II have no effect on body weight gain. Also between [I+/- IIwt] and [I+/- IItg] animals no 
statistically significant difference in the increase in weight could be found. However, a 
slightly significant difference (p<0.05) in body weight gain could be seen between [I+/+ IIwt] 
and [I+/+ IItg] mice on day 12 to 24 and 39 to 45. 
 
 
 
 
Figure 4-3: Six-day-old litter. Independent of the IGF-II transgene, 
homozygous IGF-I deficient pups are significantly smaller and are not 
synchronous in development compared to their control-littermates. 
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Figure 4-5 displays three female littermates at an age of 60 days. Whereas the wildtype 
littermate (left) is significantly taller compared to the two homozygous IGF-I deficient mice, 
no difference in body size can be seen between [I-/- IIwt] (middle) and [I-/- IItg] (right) mice, 
thus resembling the findings of the growth curve. 
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Figure 4-4: Growth curve from the early postnatal period to day 60. The data are presented as mean ± SD. 
Figure 4-5: Three female littermates at an age of 60 days. Genotypes from 
left to right [I+/+ IIwt], [I-/- IIwt], and [I-/-  IItg]. 
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4.4       Organ weight analysis 
 
Organ weight, carcass weight and nose-rump length were determined at the age of 8 weeks. 
Since the focus of this work was to investigate the effect of postnatally elevated IGF-II in the 
absence of IGF-I, we excluded the animals heterozygous for the IGF-I mutation in further 
analysis. The following statistics were based on a total number of 46 animals distributed as 
follows: 10 [I+/+ IIwt], 13 [I+/+ IItg], 21 [I-/- IIwt] and 22 [I-/- IItg]. 
 
In table 4-3 and 4-4 the absolute and relative organ weights of [I-/- IIwt] animals compared to 
[I-/- IItg], and [I+/+ IIwt] versus [I+/+ IItg] are displayed. As shown in previous studies (Wolf 
et al., 1994), a significant difference in the absolute weight of kidneys (p<0.01) and adrenal 
glands (p<0.05) between [I+/+ IIwt] and [I+/+ IItg] mice was found. Furthermore, a significant 
difference (p<0.05) of the absolute weight of the lungs was observed between these groups. 
Except for these three organs (shown again in Figure 4-6), no effect of the IGF-II transgene 
could be detected in the absolute weight of individual organs. 
 
 
 
 
No significant differences could be detected when the relative organ weight of kidneys, lungs 
and adrenal glands of [I+/+ IIwt] and [I+/+ IItg] mice were compared.  
The comparison of absolute kidney weight in [I-/- IIwt] and [I-/- IItg] mice revealed an 
increase which, however, did not reach statistical significance (p=0.07). When the relative 
weight of this organ was compared, a significant difference was found (p<0.01).  
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Figure 4-6: Absolute weights of the adrenal glands, kidneys and lungs in 60-day-old mice. Analysis of 
variance was used to evaluate statistically significant differences between indicated groups (*: p<0.05; **: 
p<0.01). 
p=0.07 
Results 
__________________________________________________________________________________________ 
56
 
 
 
A Weight (mg)  Weight (mg)  
 
Organs 
[I-/- IIwt] 
mean ± SD 
[I-/- IItg] mean ± 
SD 
∆ [I+/+ IIwt] mean 
± SD 
[I+/+ IItg] mean ± 
SD 
∆ 
Brain   311.57 ±   5.93   304.83 ±   8.19 -   458.20 ±   6.32   458.99 ±   5.73 - 
Heart   105.45 ±   4.41  103. 01 ±   4.58 -   201.17 ±   6.46   188.40 ±   5.71 - 
Lungs     79.84 ±   3.56     78.59 ±   3.70 -   180.20 ±   5.21   196.79 ±   4.60 * 
Liver   987.50 ± 46.20   927.97 ± 47.96 - 1881.75 ± 67.63 1820.67 ± 59.73 - 
Kidneys     90.28 ±   7.39   109.91 ±   7.68 -   220.77 ± 10.82   259.90 ±   9.56 ** 
Adrenal glands       2.94 ±   0.35       2.98 ±   0.39 -       7.74 ±   0.56       9.29 ±   0.45 * 
Spleen     67.47 ±   3.98     65.99 ±   4.13 -   127.47 ±   5.82   124.15 ±   5.14 - 
Pancreas     94.36 ±   5.03     92.65 ±   5.10 -   244.44 ±   7.12   236.45 ±   6.29 - 
Carcass (g)       4.59 ±   0.16       4.75 ±   0.17 -     12.22 ±   0.23     12.31 ±   0.21 - 
Body weight (g)     13.51 ±   0.46     13.82 ±   0.48 -     32.98 ±   0.68     33.30 ±   0.60 - 
NRL (cm)       7.18 ±   0.08       7.14 ±   0.09 -     10.25 ±   0.12     10.21 ±   0.11 - 
 
 
 
 
B % Body weight  % Body weight  
 [I-/- IIwt] [I-/- IItg] ∆ [I+/+ IIwt] [I+/+ IItg] ∆ 
Organs mean ± SD mean ± SD  mean ± SD mean ± SD  
Brain    2.46 ± 0.062    2.32 ± 0.085 -    1.41 ± 0.066    1.42 ± 0.060 - 
Heart    0.78 ± 0.018    0.74 ± 0.018 -    0.61 ± 0.026    0.57 ± 0.023 - 
Lungs    0.60 ± 0.012    0.57 ± 0.013 -    0.55 ± 0.018    0.59 ± 0.016 - 
Liver    7.32 ± 0.234    6.74 ± 0.243 -    5.66 ± 0.342    5.44 ± 0.302 - 
Kidneys    0.67 ± 0.024    0.79 ± 0.025 **    0.66 ± 0.035    0.76 ± 0.031 - 
Adrenal glands    0.02 ± 0.002    0.02 ± 0.002 -    0.02 ± 0.003    0.03 ± 0.003 - 
Spleen    0.50 ± 0.021    0.48 ± 0.022 -    0.40 ± 0.031    0.38 ± 0.027 - 
Pancreas    0.70 ± 0.031    0.68 ± 0.031 -    0.75 ± 0.044    0.72 ± 0.038 - 
Carcass  34.21 ± 0.704  34.73 ± 0.731 -  37.12 ± 1.031  37.06 ± 0.910 - 
NRL (cm/g 1/3)    3.05 ± 0.028    3.01 ± 0.030 -    3.24 ± 0.041    3.22 ± 0.036 - 
 
 
Table 4-3: Absolute (A) and relative (B) organ weights of [I-/- IIwt] compared to [I-/- IItg] mice and [I+/+ IIwt] 
compared to [I+/+ IItg] mice. Analysis of variance was used to determinate the absence (-) or presence (*: 
P<0.05; **: P<0.01; ***: P<0.001) of a statistically significant difference (∆) between IGF-II wildtype (IIwt) 
and transgenic (IItg) mice. 
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Organ  I II Sex I*II I*II*Sex 
  F F F F F 
Brain a 517.31 *** 0.20  1.35  0.32  0.04  
 r 200.81 *** 0.88  41.08 *** 1.02  0.94  
Heart a 285.79 *** 2.02  34.99 *** 0.93  0.74  
 r 61.75 *** 2.94  0.22  0.00  0.86  
Lungs a 639.25 *** 3.15  15.03 *** 4.26 * 1.36  
 r 0.79  0.52  9.21 ** 4.76 * 0.65  
Liver a 253.89 *** 1.16  57.21 *** 0.00  4.02 * 
 r 27.12 *** 1.96  4.66 * 0.42  1.94  
Kidneys a 244.20 *** 10.72 ** 97.83 *** 1.18  16.30 *** 
 r 0.37  13.14 *** 45.32 *** 0.20  4.96 ** 
Adrenal glands a 157.33 *** 3.21  75.87 *** 2.90  16.66 *** 
 r 4.83 * 1.63  66.50 *** 2.23  5.12 ** 
Spleen a 149.66 *** 0.25  1.50  0.04  3.84 * 
 r 16.37 *** 0.71  1.28  0.00  3.77 * 
Pancreas a 610.05 *** 0.66  21.84 *** 0.28  2.08  
 r 1.27  0.46  0.32  0.00  0.47  
Carcass  a 1529.77 *** 0.42  49.69 *** 0.04  10.80 *** 
 r 9.60 ** 0.06  6.63 * 0.14  0.46  
NRL a 958.11 *** 0.19  7.78 ** 0.00  0.22  
 r 34.30 *** 0.57  9.58 ** 0.06  1.32  
Body weight  a 1197.33 *** 0.32  77.93 *** 0.00  7.89 *** 
 
Table 4-4: Effects of IGF-I, IGF-II, sex and interactions between these factors on absolute and relative organ 
weights, nose-rump-length and body weight. Analysis of variance was used to evaluate effects of IGF-I (I; +/+ 
vs. -/-), IGF-II (II; wt vs. tg), sex and the various interactions of these factors on absolute (a) and relative (r) 
organ weights, nose-rump-length (NRL) and body weight. F values and their level of significance (*: P<0.05; 
**: P<0.01; ***: P<0.001) are shown. 
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4.5       Analysis of geometric and structural bone parameters 
 
Geometric and structural bone parameters of 53 animals were investigated: 12 (7♀, 5♂) [I+/+ 
IIwt], 12 (5♀, 7♂) [I+/+ IItg], 12 (6♀, 6♂) [I-/- IIwt], and 17 (6♀, 11♂) [I-/- IItg].  
At the femoral metaphysis, a predominantly trabecular bone site, the pQCT analyses showed 
slightly higher total volumetric BMD in male and female IGF-I knockout mice ([I-/- IIwt],   
[I-/- IItg]) relative to wildtype controls ([I+/+ IIwt], [I+/+ IItg]). In contrast, trabecular BMD 
was strongly reduced by 52% and 37% in male and female IGF-I knockout mice, respectively. 
Total cross-sectional area of the bone slices was reduced by approximately 70% in male and 
female IGF-I-ablated mice ([I-/- IIwt], [I-/- IItg]). Female mice had generally higher total but 
not trabecular BMD and lower cross-sectional area compared with male mice at the distal 
femoral metaphysis. At the femoral shaft, IGF-I-ablated mice ([I-/- IIwt], [I-/- IItg]) showed a 
pronounced reduction in bone size but unchanged total volumetric BMD compared with 
wildtype mice ([I+/+ IIwt], [I+/+ IItg]). Similar to the distal metaphysis, bone size of the shaft 
was reduced in female relative to male mice (Table 4-5).  
At both the distal femoral metaphysis and the femoral shaft, 3-way factorial ANOVA 
revealed significant interactions between sex and IGF-I, i.e., the bone phenotype of male IGF-
I knockout mice was more severe than that of female IGF-I knockouts relative to sex-matched 
wildtype controls (Table 4-5). However, most importantly, the presence or absence of the 
IGF-II transgene failed to show any significant effect on any of the geometric or BMD 
parameters in wildtype mice or in mice lacking IGF-I.  
The pQCT findings were confirmed by bone histology. Femurs of IGF-I-ablated mice ([I-/- 
IIwt], [I-/- IItg]) were much smaller in size, and showed less cancellous bone together with 
reduced cortical bone thickness in comparison with wildtype controls ([I+/+ IIwt], [I+/+ IItg]) 
(Figure 4-7). Taken together, our findings confirm previous reports by other groups (Mohan 
et al., 2003; Wang et al., 2004) of an important role of IGF-I in bone growth and in cancellous 
bone homeostasis. In the presence or absence of IGF-I, an increase of the circulating levels of 
IGF-II was without effect on the skeleton in our mouse model and could not substitute for the 
skeletal functions of IGF-I in IGF-I-ablated mice. 
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[I+/+  IIwt] [I+/+  IItg] 
[I-/- IIwt] [I-/- IItg] 
Figure 4-7: Histological sections of the femur stained with von Kossa/McNeal in 8-week-old 
mice. No histological differences could be detected when animals carrying the IGF-II transgene 
were compared to their control groups (IGF-I intact or deficient). 
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  Genotype 3-way ANOVA 
Variable  [I+/+ IIwt] [I+/+ IItg] [I-/- IIwt] [I-/- IItg] I II Sex I * II I * Sex II * Sex 
Femoral 
metaphysis            
Total BMD 
(mg/cm³) 
Males 
Females 
530±74 
567±20 
508±59 
553±41 
542±35 
619±72 
540±40 
599±63 
* - ** - - - 
Trabecular 
BMD (mg/cm³) 
Males 
Females 
297±46 
260±36 
276±45 
260±41 
144±45 
163±27 
156±21 
193±40 
*** - - - * - 
Cross-sectional 
area (mm²) 
Males 
Females 
5.32±0.46 
4.45±0.26 
5.09±0.32 
4.42±0.49 
1.53±0.24 
1.38±0.24 
1.71±0.32 
1.47±0.20 
*** - *** - ** - 
Femoral shaft            
Total BMD 
(mg/cm³) 
Males 
Females 
760±61 
725±34 
763±55 
704±34 
742±28 
718±54 
741±89 
715±74 
- - * - - - 
Cross-sectional 
area (mm²) 
Males 
Females 
2.56±0.30 
2.18±0.21 
2.49±0.24 
2.09±0.20 
0.66±0.09 
0.61±0.07 
0.72±0.10 
0.61±0.07 
*** - *** - ** - 
Cortical area 
(mm²) 
Males 
Females 
1.42±0.25 
1.17±0.12 
1.40±0.15 
1.09±0.13 
0.39±0.05 
0.36±0.05 
0.43±0.08 
0.35±0.03 
*** - *** - ** - 
Cortical 
thickness (mm) 
Males 
Females 
0.30±0.04 
0.27±0.02 
0.30±0.02 
0.25±0.02 
0.16±0.01 
0.16±0.02 
0.18±0.03 
0.15±0.01 
*** - *** - * - 
  
      Table 4-5: Bone mineral density and geometric variables of the femur in 8-week-old mice. Analysis of variance was used to evaluate statistically significant differences    
       between indicated groups (*: p<0.05; **: p< 0.01; ***: p<0.001). All values are means ± SD. BMD, bone mineral density. I, IGF-I. II, IGF-II. 
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4.6       Western ligand blot of IGFBPs 
 
A Western ligand blot was used to evaluate the serum levels of IGFBPs in [I-/- IIwt], [I-/- 
IItg], [I+/+ IIwt], and [I+/+ IItg] mice (Figure 4-8). 
 
 
 
 
 
While IGFBP-1 (~30 kDa) and IGFBP-4 (~24 kDa) levels were similar in all four groups, the 
levels of IGFBP-2 (~32 kDa) and IGFBP-3 (~39/43 kDa) varied significantly between the 
different groups. In [I-/- IIwt] the levels of IGFBP-2 (~32  kDa) and IGFBP-3 (~39/43 kDa) 
were strongly reduced but in the presence of IGF-II ([I-/- IItg]) it was partially restored. 
However, the values were still less than in the IGF-I wildtype animals ([I+/+ IIwt] and [I+/+ 
IItg]). A semiquantitave evaluation of the IGFBPs is shown in figure 4-9. 
35 kDa –
IGF-I      -/-      -/-        -/-       -/-         +/+     +/+     +/+     +/+ 
IGF-II     wt      wt        tg       tg        wt      wt       tg       tg 
45 kDa –
25 kDa –
Figure 4-8: Western ligand blot analysis from serum samples using [125]IGF-II as a 
tracer. 
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4.7       Western immunoblot for growth hormone (GH) 
 
Homozygous IGF-I deficient mice are known to have increased levels of GH. To demonstrate 
that the lack of an IGF-II effect on growth in our animals was not due to a loss of these 
elevated GH levels, a GH-Western immunoblot performed. We evaluated a large number of 
[I-/- IIwt] and [I-/- IItg] animals and observed the presence of extremely high GH levels in 
individual animals of both groups. Figure 4-10 shows a representative result using 1 µl serum 
of [I-/- IIwt], [I-/- IItg] and [I+/+ IIwt] mice. 4 ng of recombinant GH were used as a positive 
control. 
 
 
 
~22 kDa  
GH   [I-/- IIwt] [I-/- IItg] [I+/+ IIwt] 
Figure 4-10: Growth hormone Western immunoblot. 4 ng recombinant GH were used as a 
positive control (first lane). 
IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4
0.0×10-00
2.5×1005
5.0×1005
7.5×1005
1.0×1006
I -/-, II tg
I -/-, II wt
I +/+, II wt
I +/+, II tg
a
IG
F 
bi
nd
in
g 
ac
tiv
ity
 [A
U
]
Figure 4-9: Semiquantitative evaluation of the individual IGFBPs presented in 
Figure 4-8.  
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Thus, [I-/- IItg] animals still have elevated GH levels in spite of postnatally elevated IGF-II 
levels. This suggests that IGF-II cannot exert a similar negative feedback mechanism as IGF-I 
on GH release. The average GH levels in blood serum of wildtype mice were beyond the 
detection level for this assay. 
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5 Discussion 
 
5.1 Generation of double-mutant mice 
 
As described in chapter 4.1, we generated [I-/- IIwt] and [I-/- IItg] mice by a mating scheme 
in two steps. According to the Mendelian rules, the expected genotype distribution for [I-/- 
IIwt] and [I-/- IItg] animals would have been 12.5 % for each genotype. In this study the 
obtained genotype distribution was 5.3 % for [I-/- IIwt] and 6.8 % for [I-/- IItg] mice, 
indicating a mortality rate (before weaning) of 57.6 % and 46.6 %, respectively. A previous 
study of these homozygous IGF-I deficient mice on an intercross (129/Sv x C57BL/6) as well 
as on a C57BL/6J (N4) background in two different lines revealed a mortality rate of more 
than 95% (Powell Braxton et al., 1993). Liu et al. (1993) demonstrated that the survival 
frequency of homozygous IGF-deficient mice is dependent on their genetic background. On a 
129/Sv x 129/Sv and a C57BL/6J x 129/Sv background they obtained a survival rate of 10 % 
and 16 %, respectively. On a MF1 x 129/Sv background the survival rate increased to 68 %, 
indicating that the intercrossing of an outbred strain (MF1) significantly decreases the 
mortality rate of homozygous IGF-I knockout mice (Liu et al., 1993). 
This is consistent with our findings. First approaches in our lab to generate IGF-I deficient 
mice by mating of heterozygous animals ([I+/-] x [I+/-]) on the original genetic background 
revealed a mortality rate of homozygous IGF-I deficient mice of ~94 % (data not shown). On 
a 75 % NMRI outbred background the mortality rate of [I-/- IIwt] mice decreased to 57.6 %.  
These findings were not really surprising since it is well known that outbred strains due to the 
higher level of heterozygosity have longer life spans, higher disease resistance earlier fertility 
and higher overall reproductive performance and most important a lower neonatal mortality as 
compared to inbred strains (Linder and Davisson, 2004). 
 
The severe effects of the lack of IGF-I on the fertility of [I-/-] mice have been previously 
described (Baker et al., 1993) and include different alterations for both sexes. Female [I-/-] 
possess an infantile uterus and fail to ovulate. Their serum estradiol levels are reduced to 52.6 
% of normal. Male mutants have reduced testis size and vas deferens of the epididymal duct; 
seminal vesicles as well as prostate are vestigal. Moreover, their levels of spermatogenesis are 
reduced and the serum concentration of testosterone is only 18 % of normal. Both sexes of   
[I-/-] mice lack libido and are infertile. 
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Although we did not evaluate the fertility of the different groups systematically, several [I-/-] 
animals from either genders, carrying or not the IGF-II transgene, were maintained for several 
weeks in cages containing fertile animals of the opposite sex. We neither observed mating 
behaviour nor obtained a pregnancy or litter where one of the parents were [I-/- IItg]. 
Therefore, although we cannot be sure that elevated levels of circulating IGF-II have no effect 
on the reproductive organs, we are able to conclude that it does not restore the fertility in IGF-
I knockout mice. 
 
5.2  Expression analysis 
 
5.2.1 Circulating levels of IGF-I and IGF-II 
 
Previous reports already demonstrated that the serum levels of IGF-I are intermediate in 
heterozygous and below detection level in homozygous IGF-I deficient mice harbouring a 
deletion of the gene (Powell-Braxton et al., 1993). Reduced levels of this growth factor were 
also described for a 15-year old patient carrying a homozygous partial deletion of the IGF1 
gene (Woods et al., 1996). 
This is consistent with our findings. Plasma IGF-I levels measured by RIA in 60-day-old mice 
were below detection levels in [I-/- IIwt] and [I-/- II tg] mice. Intermediate levels were present 
in animals harbouring only one intact IGF-I allele ([I+/- IIwt], [I+/- IItg]) and the highest 
values were found in mice with two intact IGF-I alleles ([I+/+ IIwt], [I+/+ IItg]).  
Animals harbouring the PEPCK-IGF-II transgene ([I-/- IItg], [I+/- IItg], and [I+/+ IItg]) 
displayed a significant increase in serum IGF-II level when compared to their wildtype 
counterparts ([I-/- IIwt], [I+/- IIwt], and [I+/+ IIwt]). Thus, radioimmunoassays for serum 
levels of IGF-I and IGF-II demonstrated the expected expression of the two peptides, 
reflecting the genotype. 
 
Moreover, it was shown that the presence of the IGF-II transgene resulted in reduced levels of 
IGF-I in the groups [I+/- IItg] and [I+/+ IItg]. This has also been observed in a previous study 
on heterozygous PEPCK-IGF-II transgenic mice, which led to the assumption that the 
negative relationship between serum IGF-II and IGF-I levels might be due to displacement by 
IGF-II of IGF-I from IGFBPs (mainly the IGF/IGFBP-3/ALS-complex) leading to a rapid 
clearance of the growth factor because of the short half-life of free IGFs (Wolf et al., 1994).  
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5.2.2 Onset of PEPCK-IGF-II expression 
 
Cytosolic phosphoenolpyruvate kinase (PEPCK) is a pace-setting enzyme for 
gluconeogenesis. The gene coding for PEPCK is expressed in many tissues and regulated 
developmentally as well as in a complex tissue-specific manner (Eisenberger et al., 1992; 
Short et al., 1992). Expression of the PEPCK gene starts in the kidney several days before 
birth and in the liver at birth (Eisenberger et al., 1992). Studies of mice harbouring a bovine 
GH gene controlled by a 460 bp of the rat PEPCK promoter demonstrated that the 
PEPCK/bGH gene was not transcribed in the liver of fetal mice until immediately before birth 
(embryonic stage 19). Transcription increased about 200-fold after birth (McGrane et al., 
1990). 
Previous studies of adult PEPCK-IGF-II transgenic mice revealed expression of this transgene 
in liver, kidney and several parts of the gut. In order to determine the onset of PEPCK-IGF-II 
expression at the major expression-sites, we performed an RT-PCR of total RNA from liver 
and kidneys of embryos at day 17.5 and 19.5 as well as of pups at day 4 postnatal. Transgene 
expression of PEPCK-IGF-II in the liver could be detected from embryonic stage 19.5 
onwards. On day 4 postnatal the obtained signal was visibly stronger. These findings are 
consistent with the previous findings in PEPCK-bGH transgenic mice (McGrane et al., 1990). 
Contrasting to the findings in the liver, PEPCK-IGF-II transgene expression could not be 
detected in the kidney in any of the investigated stages. A possible explanation for this 
difference is a postponed onset of expression in this organ. This may result from differences 
in the specific features of the PEPCK-IGF-II construct which included different heterologous 
intron and terminating sequences (Wolf et al., 1994). 
However, the onset of the PEPCK-IGF-II transgene expression coincides with the time point 
when the expression of endogenous IGF-II is shut down in almost every tissue of the mouse. 
This specific expression pattern resulted to be very useful for the purpose of our investigation. 
  
 
5.3 Body weight gain 
 
To investigate the effects of postnatally elevated IGF-II on body weight gain, we recorded the 
body weight of selected litters daily starting from day 3 to 4 after birth. We did not start our 
weight records immediately after birth to avoid a further increase of the mortality rate of 
homozygous IGF-I deficient mice around this time. It is known that the handling of newborn 
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pups may cause maternal aggression and thus, increase the danger of the mother attacking the 
pups and killing or eating them (Poole, 1987). 
 
Statistical analysis of the obtained data revealed that, regardless of the presence of the 
PEPCK-IGF-II transgene, mice harbouring a deletion of the Igf1 gene exhibit a decreased 
postnatal growth rate. Homozygous ([I-/- IIwt], [I-/- II tg]) and heterozygous ([I+/- IIwt], [I+/- 
IItg]) IGF-I deficient mice displayed a significantly reduced weight as compared to IGF-I 
wildtype animals ([I+/+ IIwt], [I+/+ IItg]). When [I-/- IIwt] and [I-/- II tg] mice were compared 
to [I+/- IIwt] and [I+/- IItg] animals, also a significant reduction in body weight could be 
shown for the homozygous IGF-I knockout mice. However, visible consequences of the 
reduced body weight gain only could be observed in homozygous IGF-I deficient “dwarfs”. 
These findings are consistent with the initial description of the IGF-I knockout mice which 
were employed for our experimental design (Powell-Braxton et al., 1993). 
Comparison of [I-/- IIwt] with [I-/- II tg] and [I+/- IIwt] with [I+/- IItg] mice demonstrated that 
elevated levels of IGF-II have no significant influence on body weight gain. Thus, an increase 
in the levels of circulating IGF-II is not able to rescue growth deficits in mice with a 
heterozygous or homozygous deletion of the IGF-I allele in the postnatal period.  
 
In a previous study of PEPCK-IGF-II animals, a slight (even though not significant) increase 
in body weight could be observed in the IGF-II transgenic animals when compared to their 
wildtype controls (Wolf et al., 1994). This tendency could also be observed in our study. 
Moreover, the weight difference between [I+/+ IIwt] and [I+/+ IItg] animals reached statistical 
significance on day 12 to 24 and 39 to 45. A possible explanation for this observation is the 
different genetic background of the mouse strain employed in each study. 
 
5.4 Organ weight analysis 
 
IGF-I is well known to play an important role not only in fetal development but also in 
postnatal growth (reviewed in Efstradiatis, 1998). Postnatally elevated serum levels of IGF-II 
have already been shown to exert subtle time-specific effects on organ growth (Wolf et al., 
1994). The initial description of the PEPCK-IGF-II transgenic mouse model employed in our 
study revealed a significantly greater kidney weight of the transgenic animals at the age of 4 
weeks as compared to age-matched controls. At an age of 12 weeks, no significant difference 
in kidney weight could be observed but transgenic mice displayed significantly higher 
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weights of the adrenal glands than controls. Consistent with these findings, we observed that 
the absolute weight of kidneys and adrenal glands in our [I+/+ IItg] mice was significantly 
increased at an age of 8 weeks when compared to their controls ([I+/+ IIwt]). The effects of 
elevated IGF-II on the growth of kidneys and adrenal glands have been already 
comprehensively discussed in Wolf et al. (1994). Moreover, our studies indicate an additional 
effect of IGF-II on the lung, since we could detect a significant increase of the absolute 
weight in this organ. A possible explanation for this finding would be the different genetic 
background of the mice used in this study. Anyway, this is a very interesting finding which 
deserves further investigation. Specially, stereological analysis of this organ would help to 
clarify the specific sites of the size increase. 
Interestingly, the relative organ weight of adrenal glands, kidneys and lungs was not elevated 
in the [I+/+ IItg] animals. The most probable explanation for this finding is that in the 
calculation of the relative organ weights, the significant increase of weight of these organs 
vanished due to the observed slight increase in body weight of [I+/+ IItg] mice.  
 
Evaluation of the organ weight of the [I-/- IIwt] and [I-/- II tg] mice revealed no significant 
difference of the absolute organ weight between these two groups. Contrasting to this finding, 
the relative organ weight of the adrenal glands was significantly increased in the [I-/- II tg] 
animals. This is apparently intriguing but can be explained by the fact that the absolute weight 
of the kidneys was already increased in [I-/- IItg] mice but only reached borderline 
significance (p=0.07). 
 
5.5 Bone parameters 
 
The IGF system is thought to play an important role in bone physiology, especially in the 
regulation of BMD. In fact, the IGFs are profusely produced by osteoblasts and are the most 
abundant growth factors stored in bone (Yakar and Rosen 2003). To complement the analysis 
of growth presented here (based mainly on body and organ weights), we examined the 
geometric and structural properties of a long bone (femur), a system in which the IGF system 
has been extensively studied. pQCT analyses revealed an array of significant differences 
between [I-/-] and [I+/+] animals, regardless of the presence of the IGF-II transgene. Most of 
these alterations have been already described in previous studies (see below). The most 
obvious phenotype was a generalized reduction in bone size. In addition, at the femoral 
metaphysis, IGF-I knockout mice displayed a moderately higher total volumetric BMD but 
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strongly reduced trabecular BMD and cross-sectional area of bone slices. At the femoral shaft, 
total volumetric BMD was unchanged. Interestingly, 3-way factorial ANOVA identified 
significant interactions between sex and IGF-I (when compared to sex-matched wildtype 
control animals, bone parameters of male IGF-I knockout mice were more severely affected 
than those of females). This is a remarkable finding considering the strongly reduced levels of 
circulating sex hormones (Baker et al., 1996). Histological analyses of the femur confirmed 
these findings. In addition to a reduction in size, IGF-I knockout mice showed less cancellous 
bone and reduced cortical thickness when compared to control animals. More importantly, 
however, elevated circulating levels of IGF-II in [I-/- IItg] and [I+/+ IItg] animals failed to 
exert any significant effect on any of the evaluated parameters when compared to the 
respective control groups. 
 
Smaller bones and delayed ossification were among the first alterations observed in IGF-I 
knockout mice (Liu et al., 1993; Baker et al., 1993; Powell-Braxton et al., 1993). Further 
studies revealed, among other effects, a reduction in the size of hypertrophic chondrocytes in 
the femur (Lupu et al., 2001), in tibial bone formation rate (Bikle et al., 2001) and in femoral 
BMD (Mohan et al., 2003). In accordance with these data, overexpression of IGF-I in 
osteoblasts increased peak BMD (Zhao et al., 2000). Recently, Wang et al. (2004) compared 
the size and growth plate parameters in homozygous IGF-I deficient and homozygous growth 
hormone receptor knockout (GHR) mice. Animals lacking GHR displayed a stronger 
reduction in bone size and more severe effects in the growth plate as compared to the 
alterations observed in mice lacking IGF-I. Based on the observation that IGF-II is expressed 
in the germinal and proliferative zones of the growth plate (Shinar et al., 1993; Wang et al., 
1995), the authors hypothesized that the effects of GH on chondrocyte generation and 
proliferation may be mediated by GH-induced IGF-II expression. In fact, the authors were 
able to measure increased levels of IGF-II in the growth plate of IGF-I knockout mice and 
reduced levels of this growth factor in GHR knockout animals (Wang et al., 2004). Although 
we did not evaluate growth plate parameters, our results are not in agreement with this theory. 
This difference can have at least two explanations. First, the potential growth-promoting 
effects of IGF-II in the growth plate are not strong enough to result in an increase in the 
structural parameters examined. Second, the growth-promoting effects of IGF-II in the growth 
plate are mediated exclusively by locally produced IGF-II, which may not be elevated in our 
experimental model. 
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5.6 Western ligand blot of IGFBPs  
 
The six IGF-binding proteins (IGFBP-1 to -6) are expressed in a tissue-specific manner and 
act as modulators of IGF activity. Western ligand blot analyses represent a well-established 
method to detect bioactive IGFBPs in blood serum (Hossenlopp et al., 1986). Evaluation of 
the serum levels of IGFBPs in [I-/- IIwt], [I-/- IItg], [I+/+ IIwt], and [I+/+ IItg] animals revealed 
that the levels of IGFBP-1 and IGFBP-4 were similar in all four groups. This was not true for 
the levels of IGFBP-2 and IGFBP-3 which differed significantly between the groups. The 
levels of both binding proteins were strongly reduced in the [I-/- IIwt] mice but in the 
presence of IGF-II ([I-/- IItg]) their levels were partially restored. However, postnatally 
elevated levels of IGF-II in homozygous IGF-I deficient ([I-/- IItg]) mice were not able to 
completely compensate the lack of IGF-I, since their values of IGFBP-2 and -3 were still 
lower than in the IGF-I wildtype animals ([I+/+ IIwt] and [I+/+ IItg]). 
These findings indicate that the IGFBPs are differentially regulated by IGF-I and IGF-II. 
While the IGFs may exert this effect by directly influencing the expression of these IGFBPs, a 
possible alternative explanation would be that they regulate the IGFBP levels by a post-
translational mechanism, e.g. influencing their stability in blood circulation. 
 
5.7 Growth hormone Western immunoblot 
 
Both growth hormone and IGF-I are important for postnatal growth. GH partially mediates its 
growth promoting effect by upregulation of IGF-I expression in many tissues, especially the 
liver, but also exerts IGF-independent effects (Le Roith et al., 2001). 
Growth hormone is synthesized and released from the anterior pituitary in a pulsatile manner.  
In wildtype mice the average value for GH in the blood serum is ~10 ng/ml for females and 
~16 ng/ml for males (McLeod et al., 1991). IGF-I negatively regulates GH release through a 
feedback mechanism, inhibiting GH synthesis and release by the anterior pituitary. Lupu et al. 
(2001) already demonstrated that homozygous IGF-I deficient mice display increased levels 
of GH. 
To exclude the possibility that the lack of an IGF-II effect on growth in our animals was due 
to a loss of these elevated GH levels, the blood serum of a large number of [I-/- IIwt], [I-/- 
IItg], and [I+/+ IIwt] animals was evaluated by GH-Western immunoblot.  For wildtype ([I+/+ 
IIwt]) animals no signal could be detected. This was because the amount of GH in the 
wildtype serum was below detection limit of this assay. Moreover, it could be demonstrated 
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that, despite postnatally elevated IGF-II levels, [I-/- IItg] animals still have elevated GH 
levels. 
Thus, the lack of growth effect of postnatally elevated levels of IGF-II in the absence of IGF-I 
is not caused by reduced levels of GH. Furthermore, these results suggest that circulating 
IGF-II cannot exert a similar negative feedback mechanism as IGF-I on GH release. 
 
5.8 Final considerations 
 
Our results support the notion that, in spite of a high degree of structural homology and a 
common signaling receptor, IGF-I and -II have distinct functions. This is particularly evident 
when we consider their role in animal growth (see Efstratiadis, 1998). During embryonic 
development when both growth factors are naturally present at high concentrations, one 
cannot compensate the growth impairment observed in the (experimentally induced) absence 
of the other one (knockout mice lacking IGF-I or -II are both born with a weight ~60% N). 
Previous studies involving administration of IGF-II or the generation of transgenic mice 
overexpressing this growth factor failed to show any effect on postnatal growth. We show that 
in mice, a species in which IGF-II expression is normally discontinued after birth, restoration 
of substantial circulating levels of this growth factor does neither stimulate body weight gain 
and skeletal development nor affects considerably the weight of individual organs even in the 
complete absence of IGF-I. The reasons for this striking observation can only be speculated 
on at the moment. 
 
Since the actions of a growth factor obviously depend on its affinity to a specific receptor, an 
important point to be discussed concerns the affinity of the IGFs to the IGF-IR. Early studies 
suggested that the IGF-IR binds IGF-I with 10-30 times higher affinity than IGF-II (Heaton et 
al., 1984; Beguinot et al., 1985; Kiess et al., 1987; Ewton et al., 1987; Kadowaki et al., 1986). 
However, many subsequent reports indicate that the IGF-IR has an almost equal affinity for 
IGF-I and IGF-II (see, for instance, Steele-Perkins et al., 1988; Perdue et al., 1991). The 
reason for these differences may be related to the use of recombinant peptides of higher purity 
in latter studies but can also result from the presence of different receptor forms (discussed in 
Steele-Perkins et al., 1988). Species-specific differences may also play a role. Whatever the 
case may be, the IGFs can be considered to have a comparable affinity to the IGF-IR 
(Blakesley et al., 1996). 
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A much more probable explanation for our results is that, after activation of the IGF-IR, a 
different set of signaling pathways are initiated depending on which IGF activated the 
receptor. Little attention has been given to this issue by researchers so far but exactly this 
point may provide important clues for solving the “IGF-II enigma”. 
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6 Summary 
 
Consequences of postnatal insulin-like growth factor II overexpression in insulin-like 
growth factor I deficient mice 
 
Insulin-like growth factor I (IGF-I) and -II (IGF-II) are single chain peptides produced by 
many tissues, functioning in an endocrine, autocrine or paracrine fashion to regulate cellular 
proliferation, survival and differentiation. IGF actions are initiated upon binding to the 
insulin-like growth factor I receptor (IGF-IR) and are modulated through interactions with a 
family of six secreted IGF-binding proteins (IGFBP-1 to -6). 
IGF-I is necessary for normal growth and differentiation during both, embryonic and postnatal 
development. IGF-II is a stimulator of fetal growth but its functions in the postnatal period are 
still unclear. Notably, expression of IGF-II is shut down shortly after birth in rodents (but not 
in humans). 
 
Previous studies in phosphoenolpyruvate-carboxykinase (PEPCK)-IGF-II transgenic mice 
demonstrated that overexpression of IGF-II resulted in disproportionate growth of specific 
organs but a significant increase in body size was not observed. Homozygous IGF-I deficient 
mice were shown to be severely retarded in growth. The aim of this study was to test whether 
elevated levels of circulating IGF-II can rescue the dwarfism in IGF-I deficient mice and 
thereby function as a stimulator of postnatal growth in the absence of IGF-I. 
 
For this purpose, we crossed heterozygous IGF-I deficient mice [I+/- IIwt] with heterozygous 
IGF-I deficient mice carrying PEPCK-IGF-II transgenes [I+/- IItg]. The resulting offspring 
comprised six different groups: homozygous IGF-I knockout and PEPCK-IGF-II wildtype 
mice [I-/- IIwt], homozygous IGF-I knockout and PEPCK-IGF-II transgenic mice [I-/- IItg], 
animals lacking one IGF-I allele and wildtype for the PEPCK-IGF-II transgene [I+/- IIwt], 
lacking one IGF-I allele and harbouring the PEPCK-IGF-II transgene [I+/- IItg], wildtype for 
the IGF-I mutation and carrying the PEPCK-IGF-II transgene [I+/+ IItg], and completely 
wildtype [I+/+ IIwt]. The genotype of all mice was determined by PCR.  
Body weight of mice was recorded daily until the age of 8 weeks. The nose-rump length 
(NRL) and the weights of individual organs and of the carcass were recorded and the femurs 
and lumbar vertebras prepared for further investigations. 
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At an age of 8 weeks, mean serum concentrations of IGF-I were beyond detection level in    
[I-/- IIwt] and [I-/- IItg] mice, intermediate in [I+/- IIwt] and [I+/- IItg] animals and highest in 
[I+/+ IIwt] and [I+/+ IItg] mice. IGF-II levels were significantly increased in animals 
harbouring the PEPCK-IGF-II transgene ([I-/- IItg], [I+/- IItg], and [I+/+ IItg]) when compared 
to their wildtype counterparts ([I-/- IIwt], [I+/- IIwt], and [I+/+ IIwt]). This reflected the 
genotype, demonstrating the appropriateness of our experimental model. 
Analysis of body weight data from day 3-4 after birth until day 60 revealed that in the absence 
of IGF-I, elevated levels of IGF-II have no effect on body weight gain. The same was found 
for the nose-rump length and the carcass. The weight of specific organs, however, was 
altered. Compared to the wildtype counterparts ([I-/- IIwt]), the relative kidney weight in [I-/- 
IItg] mice was significantly increased. 
IGF-I is known to play an important role in bone growth and in cancellous bone homeostasis. 
Investigations of geometric and structural bone parameters showed that in the presence or 
absence of IGF-I, an increase in the circulating levels of IGF-II was without effect on the 
skeleton and could not substitute for the skeletal functions of IGF-I in IGF-I-ablated mice. 
Homozygous IGF-I deficient mice are known to have elevated levels of growth hormone 
(GH). To demonstrate that the lack of effect on growth in our [I-/- IItg] animals was not due 
to a loss of these elevated GH-levels, a GH-Western immunoblot was performed, revealing 
that, despite elevated levels of IGF-II, increased levels of GH were still present in [I-/- IItg] 
animals. 
Evaluation of the serum levels of IGFBPs by Western ligand blot analysis demonstrated that 
IGFBP-1 and IGFBP-4 levels were similar in all groups, whereas the levels of IGFBP-2 and 
IGFBP-3 were strongly reduced in [I-/- IIwt] animals. In the presence of IGF-II ([I-/- IItg]), 
they were partially restored but the amounts were still smaller than in the IGF-I wildtype 
animals ([I+/+ IIwt] and [I+/+ IItg]).  
 
In summary, these results show that under our experimental conditions, IGF-II is not able to 
rescue the postnatal growth deficit of IGF-I knockout mice and apparently does not exert a 
negative feedback on the secretion of growth hormone. However, it could be demonstrated, 
that the IGFs have differentiated effects on the regulation of the expression/stability of 
individual IGFBPs. 
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7 Zusammenfassung 
 
Konsequenzen dauerhaft erhöhter Spiegel des Insulin-ähnlichen Wachstumsfaktors II in 
Insulin-ähnlichen Wachstumsfaktor I defizienten Mäusen 
 
Die in vielen Körpergeweben gebildeten Insulin-ähnlichen Wachstumsfaktoren I (IGF-I) und 
II (IGF-II) regulieren auf endokrinem, autokrinem oder parakrinem Weg Zellwachstum,          
-teilung und -tod. Ihre Wirkung vermitteln sie durch Bindung an die IGF-I-Rezeptoren. Im 
Blut zirkulieren sie meist gebunden an eines der sechs IGF-Bindungsproteine (IGFBP-1 bis    
-6), die ihre Halbwertszeit wie auch Verfügbarkeit für ihre Rezeptoren beeinflussen.  
Sowohl in der embryonalen als auch postnatalen Entwicklung ist IGF-I von entscheidender 
Bedeutung für ein normales Wachstum. Zwar stimuliert auch IGF-II die vorgeburtliche 
Entwicklung, seine Funktionen nach der Geburt sind jedoch weitgehend unklar. Während bei 
Nagern die Expression von IGF-II kurz nach der Geburt eingestellt wird, können beim 
Menschen lebenslang hohe IGF-II-Spiegel im Blut nachgewiesen werden.  
 
In früheren Untersuchungen PEPCK-IGF-II transgener Mäuse konnte gezeigt werden, dass 
eine Überexpression von IGF-II zu einem vermehrten Wachstum einzelner Organe führt, 
allerdings keine signifikanten Auswirkungen auf die Körpergröße hat. Bei homozygot IGF-I 
defizienten Mäusen hingegen war ein stark vermindertes Körperwachstum zu beobachten. Die 
vorliegende Studie sollte klären, ob erhöhte IGF-II-Spiegel im Blut die Zwergwüchsigkeit 
IGF-I defizienter Mäuse kompensieren und somit postnatales Wachstum in Abwesenheit von 
IGF-I stimulieren können.   
 
Zu diesem Zweck wurden heterozygot IGF-I defiziente Mäuse [I+/- IIwt] mit heterozygot 
IGF-I defizienten / PEPCK-IGF-II transgenen Mäusen [I+/- IItg] verpaart. Aus dieser 
Kreuzung resultierten sechs verschiedene Gruppen: [I-/- IIwt], [I-/- IItg], [I+/- IIwt], [I+/- IItg], 
[I+/+ IIwt] und [I+/+ IItg] Mäuse. Der Genotyp sämtlicher Tiere wurde mittels PCR bestimmt 
und die Gewichtsentwicklung täglich bis zur achten Lebenswoche aufgezeichnet. Nach dem 
Tod der Tiere wurden Nasen-Rumpf-Länge, die Organgewichte und das Karkassengewicht 
ermittelt sowie die Oberschenkelknochen und Lendenwirbel für weitere Untersuchungen 
entfleischt.  
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Messungen der durchschnittlichen Serenspiegel für IGF-I und -II in acht Wochen alten Tieren 
zeigten, dass die ermittelten Werte den genetischen Status der Tiere widerspiegelten und 
somit die Eignung des eingesetzten Versuchsmodells bestätigten. Weder die statistische 
Analyse von Körper- und Karkassengewicht noch die der Nasen-Rumpf-Länge wies darauf 
hin, dass erhöhte IGF-II-Spiegel im Blut Gewicht und Wachstum in IGF-I defizienten Mäusen 
beeinflussen. Allerdings steigerte sich das relative Nierengewicht von [I-/- IItg] Mäusen im 
Vergleich zu ihren [I-/- IIwt] Kontrollen signifikant.  
 
Frühere Studien genetisch veränderter Mäuse wiesen IGF-I als einen entscheidenden Faktor 
für Umfang, Dichte und Längenwachstum des Knochens aus. Die hier durchgeführten 
Untersuchungen verschiedener Knochenparameter verdeutlichten, dass unabhängig vom IGF-
I-Status ein erhöhter Serumspiegel von IGF-II keine Wirkung auf das Skelett hat. IGF-II war 
also nicht in der Lage, die Funktionen von IGF-I in Bezug auf den Knochenstoffwechsel in 
IGF-I defizienten Mäusen zu übernehmen. Um auszuschließen, dass eine Reduzierung des bei 
[I-/- IIwt] Mäusen normalerweise stark erhöhten GH-Spiegels das mangelnde Wachstum in   
[I-/- IItg] Tieren bedingt, wurde ein GH-Western Immunoblot durchgeführt. Trotz eines 
erhöhten IGF-II-Spiegels blieb der GH-Spiegel in [I-/- IItg] Mäusen unverändert. Die 
Evaluierung der Serum-IGFBP-Spiegel mit Hilfe eines Western Ligandenblots ergab 
gleichbleibende IGFBP-1- und -4-Spiegel in allen Gruppen. Während in [I-/- IIwt] Tieren die 
IGFBP-2- und -3-Werte stark reduziert waren, steigerten sie sich in Anwesenheit von IGF-II 
([I-/- IItg]), erreichten jedoch nicht das Niveau von Wildtyp IGF-I-Tieren ([I+/+ IIwt] und [I+/+ 
IItg]).   
 
Unter den hier gegebenen experimentellen Bedingungen ist IGF-II nicht in der Lage, den 
postnatalen Zwergwuchs IGF-I defizienter Mäuse auszugleichen. Außerdem scheint IGF-II 
nicht die Ausschüttung des GH durch einen negativen Rückkopplungsmechanismus zu 
regulieren. Allerdings wurde eine unterschiedliche Wirkung der IGFs auf die Regulation der 
Expression / Stabilität der IGFBPs nachgewiesen.  
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